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Summary  
Current guidelines recommend opioid therapy to chronic non-malignant pain (CNP) patients when 
the benefits for pain and function outweigh risks. This systematic review examined the effects of 
opioid therapy on sleep – a valued functional outcome– in CNP. Electronic and hand searches of 
relevant studies up through July 2017 identified 18 eligible studies providing data from 3,746 CNP 
patients for analysis. Twelve of these studies were randomised controlled trials (RCTs) of up to 12-
month in duration. Low-medium dosed oxycodone and transdermal fentanyl were the most tested 
therapies (n=4 each). Only two studies used objective sleep measure in addition to self-report ratings, 
questionnaires or sleep diary. Whilst calmer sleep with less body/leg movements and fewer 
awakenings could be achieved following opioid therapy, these might occur with increased sleep-
disordered breathing and a much-shortened rapid eye movement (REM) sleep latency. Both the 
narrative synthesis and exploratory meta-analysis suggest that opioid therapy in CNP is associated 
with improved self-reported sleep quality. However, the effect is inconsistent, small (Standardised 
Mean Difference = 0.36), and may be accompanied by excessive daytime sleepiness. As a Cochrane-
recommended assessment revealed “unclear” or “high” overall risk of bias for all studies, future 
opioid trials of stronger methodology and better reporting are needed to confirm and elucidate the 
effect. 
 
 
 
Keywords: opioid; analgesics; chronic pain; sleep quality; sleep architecture; insomnia; sleepiness; 
side effect 
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Glossary 
AEs Adverse events 
AHI Apnoea-hypopnoea index 
CAI Central sleep apnoea index 
CNP Chronic non-malignant pain 
EORTC-QLQ-30 European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire 
ESS Epworth Sleepiness Scale 
MME Morphine milligram equivalent  
MOS Sleep Scale Medical Outcomes Study Sleep Scale 
MPI Multidimensional Pain Inventory 
NSAIDs Non-steroid anti-inflammatory drugs 
PSG Polysomnography 
PSQI Pittsburgh Sleep Quality Index 
RCT(s) Randomised controlled trial(s) 
REM Rapid eye movement (sleep) 
SDB Sleep-disordered breathing 
SMD Standardised mean difference(s) 
SPAASMS SPAASMS score card (one item for each: S- Score for pain, P- Physical 
activity levels, A- Additional pain medication, A- Additional 
Physician/ER Visits, S- Sleep, M- Mood, S- Side effects) 
SWS Slow wave sleep  
VSH Verran and Snyder Halpern Scale 
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1. Introduction  
 
Opioids are potent analgesics with evidence of efficacy for short-term use (i.e., maximum 12 weeks) 
(1). The effectiveness and safety of opioids therapy for chronic non-malignant pain (CNP), however, 
has become controversial following liberalised prescriptions (2-5) that coincided with an increase in 
fatalities and adverse outcomes (6, 7).  
 
Decisions regarding the introduction or discontinuation of opioid therapy are complex (8), requiring 
clinicians to balance the potential risks and benefits based on patients’ presentation of symptoms, 
comorbidities, and psychosocial circumstances (9). Current guidelines recommend non-opioid therapy 
as the preferred treatment of CNP, with opioids reserved to situations “when benefits for pain and 
function are expected to outweigh risks” (1, 10). Whilst the effectiveness of opioid therapy is usually 
measured in terms of pain outcomes, less is known about its effect on day-to-day functions. A 
particular function of concern to patients with CNP is the ability to get a good night’s sleep (11-13). 
 
Opioid medications can induce different patterns of sleep-disordered breathing (SDB), including 
central or obstructive apnoea, hypopnea, respiratory ataxia and non-apnoeic hypoxemia, with dose-
dependent effects (14-16). The prevalence of central sleep apnoea (defined as a >10-second absence of 
airflow with the lack of breathing efforts) is estimated at 24% among patients taking chronic opioid 
medications (17). Awareness of such respiratory depression effect has led to the recommendation to 
assess SDB when prescribing opioids for CNP (1, 10). However, no review has detailed the effect of 
opioid therapy on sleep quality.  
 
The pain-sleep relationship is typically described as bi-directional (18, 19). A growing body of 
experimental and observational research has found evidence in support of pain being a trigger or risk 
factor of poor sleep and poor sleep, in return, an aggravator of pain (20, 21). Further, a recent systematic 
	 6 
review has shown that a decline in sleep quality or quantity is prospectively associated with not only 
an elevation of inflammatory markers, but also an increase in risk of developing a pain condition and 
of reporting poorer physical functioning status in the long term (22). In this context, it is a common 
clinical assumption that - on the positive side of the equation – pain relief achieved with opioid 
therapy should bring about an overall improvement in sleep quality (23). However, several lab-based 
studies have linked the use of opioids such as morphine, methadone and tramadol to a dose-related 
suppression of slow wave sleep (SWS) and rapid eye movement sleep (REM), as well as an increase 
in shallower stages of Non REM sleep (particularly stage N2 sleep) (24-27). Additionally, new evidence 
based on the analysis of health information of >8400 community dwellers suggests that insomnia is 
42% more likely among people prescribed opioids than non-opioid users (28). These findings raised 
the possibility that opioid therapy may actually worsen rather than improve sleep quality.  
 
The current systematic review aimed to provide a timely examination of this issue by evaluating 
objectively measured and self-reported sleep outcomes in randomised controlled trials (RCTs) and 
other clinical trials where opioids were introduced de novo or on a switch from a lower dosed opioid 
analgesic in CNP. Instead of focusing on SDB for which there is already mounting evidence (14, 16, 29), 
the primary outcomes of interest were objectively measured sleep architecture and self-reported sleep 
quality following the introduction of opioid therapy – although SDB findings were also reported to 
inform the balance of benefits and risks. In addition, attention was given to negative sleep-related 
adverse events (AEs) reported by patients following opioid initiation, to provide a novel and broader 
risk-benefit evaluation of opioid therapies for CNP.  
2. Methods 
2.1 Data source and search strategy 
The data source for this systematic review was original studies that specifically evaluated the effect 
of introducing opioid therapy on sleep or that included measures of sleep as a secondary outcome in 
the assessment of the new opioid therapy in adult patients with CNP. The relevant medical literature 
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was identified through both electronic searches performed using PubMed MEDLINE and hand 
searches of reference lists of included studies, relevant reviews and grey literature on the topic. The 
PubMed search was carried out by a member of the review team (MTS) for the period from the 
inception of the database to 7th of July 2017, using search terms selected following several rounds of 
pilot searches to ensure comprehensive coverage (see Supplementary Materials 1). The structure of 
the search terms aimed to identify articles concerned with the use of opioid therapy; for CNP; 
examining the effect of such therapy on sleep; in adult humans. The protocol of this systematic review 
is registered with PROSPERO – International Prospective Register of Systematic Reviews 
(registration number: CRD42018089139). 
  
2.2 Selection criteria 
All articles identified through the search were subject to a title and abstract screen followed by a full-
text screen, both of which were aided with a study selection checklist, co-developed by MTS and NT 
according to our a priori list of inclusion and exclusion criteria.  
 
Specifically, the criteria specified that the participants of the included studies had to be (1) adults 
aged 18 years or above, (2) with CNP, (3) for at least 3 months at inclusion, and that these participants 
(4) were provided with opioid analgesics for pain, (5) with sleep measured as either a primary or 
secondary outcome. (6) The research design of the included studies was restricted to treatment studies 
- controlled or uncontrolled - only; (7) case studies or case-series with a sample size of ≤5 were 
excluded for concerns of high risks of bias. Further, studies were excluded if (8) the participant’s 
mean duration of CNP was not specified in the report to confirm the presence of chronic pain or 
provided by the authors via email correspondence; (9) the patients had comorbid sleep apnoea, a 
coexisting significant physical or psychiatric illness and/or substance abuse or dependence; (10) the 
trial included the use of a concurrent pharmacotherapy or psychological intervention for pain, sleep 
	 8 
or mood, except for rescue medication for breakthrough pain; (11) the full-text version of the study 
was published in a language other than English, German or Italian.  
 
2.3 Search results 
Figure 1 depicts the process of the study selection. The initial electronic search returned a total of 
2010 records, of which 255 passed the titles and abstract screen. An additional 21 articles were 
identified on the basis of citations and reference lists. Of the 104 articles read, 18 met all inclusion 
and exclusion criteria on the selection checklist and were included in the analysis below.  
 
(Insert Figure 1 about here) 
 
2.4 Data extraction 
Methodological characteristics and key findings of the included studies were extracted by MTS and 
TB using a pro forma, and then verified by HS, CB and NT. Differences in opinions were resolved 
via discussion. In the methodological characteristics table (Table 1), we summarised the studies’ 
design; type of opioids used; participants’ pain-related characteristics, age and gender at baseline; 
size of the sample receiving and finishing treatment; and the measure(s) used to assess sleep. In the 
key findings table (Table 2), we described the opioid analgesic used in greater detail and calculated 
the morphine milligram equivalent (MME) - according to the Agency Medical Directors’ Group 2015 
Interagency Guideline on Prescribing Opioid for Pain (30), except for buprenorphine (sublingual and 
transdermal), for which the Faculty of Pain Medicine of the Australian and New Zealand College of 
Anaesthetists conversion table was used (31). We also tabulated the number, timing and reasons of 
attrition; the number, timing and nature of any sleep-related AEs reported. Finally, we reported the 
relevant outcomes of each study on sleep and pain. When the relevant information was missing, the 
corresponding author of the article was contacted by email, with another follow-up email sent after 4 
weeks if no response. Requests were sent out for additional information from 18 studies. Six authors 
responded, four provided the requested information.  
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2.5 Data synthesis 
A narrative approach was chosen for the current review, given the heterogeneity in design and 
outcome measures used in the studies reviewed. Results of the analysis were described in the text 
based on the methods and principles recommended by the Cochrane Collaboration (32). A preliminary 
synthesis was first developed by describing key features of each study equally. The synthesis was 
then streamlined to report methodological characteristics and key findings of studies according to 
their research design (e.g., RCT or not), type of opioid therapy tested, sample of interest, whether 
sleep was a primary outcome measure, and the nature of the sleep measure (e.g., objective vs. self-
reported; validated vs. non-validated).  
 
The reporting was centred on the hypothesis that the introduction of opioid therapy would have an 
effect on sleep. Evidence in support of a positive and a negative effect was presented with a tally of 
the number of studies generating such evidence. Considering that the aim of the current review was 
to examine the effect of opioids on sleep architecture and self-reported sleep quality, we presented 
the findings on objective sleep measures first, and then the self-reported findings based on 
questionnaires, ratings, and self-reports of AEs.  
  
As an attempt to quantitatively synthesise the data collated, an exploratory meta-analysis was 
conducted with a restricted set of data from RCTs comparing the effect of opioid therapy with placebo 
or no-opioid therapy (e.g., Non-steroid Anti-inflammatory Drugs, NSAIDs, only). Given the variety 
of sleep outcome measures used, only RCTs that had a quantitative indicator of sleep quality 
expressed in the form of a composite sleep score, a visual analogue or numerical rating, or the number 
of sleep hour met the minimal requirement of comparability (33-37). RCTs that examined more than 
one opioid treatment arm had more than one comparison in the forest plot, and hence the total number 
of participants involved was reported based on the number of people in the opioid rather than the 
	 10 
control group. Standardised mean differences (SMD) between the “Opioids” and the “Control” 
groups were estimated using a random effect model. Statistical heterogeneity among studies was 
assessed with I2 statistics along with visual inspection of the forest plots. Funnel plots were also 
presented to allow visual examination of potential publication biases.  
 
2.6 Risk of bias assessment 
Six main categories of bias were considered: random sequence generation (selection bias), allocation 
concealment (selection bias), blinding of participants and personnel (performance bias), blinding of 
outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting 
(reporting bias). In addition, potential conflicts of interests in the conduct of the studies were 
considered (other bias). The Cochrane recommended appraisal process for RCTs (32) was also used 
for the seven non-RCT studies in order to compare risk of bias across all study designs.  
 
TB, NT and HS carried out the assessment independently. A judgement of “high risk”, “low risk” or 
“unclear risk”, with supporting evidence, was given to each category of bias by each assessor for each 
included study. Results of these independent assessments were then pooled and discussed with the 
full review team. Differences in opinion were resolved via discussion. The final assessment was 
summarised in text and visually presented in the form of a risk of bias graph and summary. The 
overall risk of bias of each study was then categorised into “high”, “unclear”, “low”, according to the 
Cochrane definition (32). The results were then inserted into the last column of Table 2.   
3. Results 
3.1 Overview 
The 18 included articles were published between 1997 and 2016, involving a total of 3746 CNP 
patients (starting sample size range: n=12 to n=749; mean age at baseline: 43-66 years; enrolled 
female%: 38%-79%). The majority of the studies were conducted in the US (n=11; 61%), followed 
by two studies from Canada (10%); one study each from Australia, China, Norway, and Sweden; and 
one multicentric international study (Canada, Czech, Hungary, Poland, Slovakia, UK) (see Table 1).  
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(Insert Table 1 about here)  
 
3.2 Characteristics of the included studies 
Twelve (67%) were RCTs (33-44)(Table 1). Among these RCTs, eight compared the opioid therapy of 
interest directly with a placebo or control group using a parallel-group design (34, 36, 38-43). Four 
involved a titration run-in phase before randomisation, to evaluate the effect of different opioid 
regimens in the “safety sample” using an enriched enrolment withdrawal or crossover design (35-37, 44). 
One RCT adopted a repeated-dose design with five phases, including an experimental phase in which 
participants were randomly assigned to set-dose oxycodone vs. titrated-dose oxycodone plus 
morphine sulphate vs. naproxen (33)). The remaining six studies (41.6%) were non-RCTs (45-50): five 
were non-randomised single-treatment studies (45-47, 49, 50), and one a feasibility study (48). 
 
The opioid analgesics being evaluated varied in type, dose, and administration route between studies. 
The most common opioids were morphine sulphate (34, 43, 45, 49)  , oxycodone (33, 38, 41, 43), and 
transdermal fentanyl (40, 46, 48, 50). The other opioids were: tramadol (35, 36, 39), transdermal 
buprenorphine (39, 48), hydromorphone (37, 38), methadone (34, 47), buccal buprenorphine (44), 
transmucosal fentanyl citrate (46), and codeine (42). The mean opioid doses varied from low (<50 
MME/day) (33, 35-37, 39, 42, 49) to medium (50-100 MME) (34, 43, 45, 49, 50), high (101-199 MME) (40), and 
very high (>200 MME) (46, 47). Four studies did not report the mean values of the doses administered 
(38, 41, 44, 48). In terms of the maximum dose allowed, two of the four (50%) studies that used fentanyl 
fell into the very high dose category(40, 46). The other very high dose study used methadone (47). 
Unsurprisingly, tramadol and codeine studies were in the low doses (35, 36, 39, 42). The morphine studies 
were all in the medium range (34, 43, 45, 49). 
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Eleven (61%) of the studies allowed rescue medications for breakthrough pain, in addition to the 
opioids being tested (34-37, 39, 40, 42-44, 48, 50). Specifically, four allowed rescue medications in the form 
of paracetamol or ibuprofen. The dosage allowed ranged from a maximum of 1000 mg paracetamol 
a day (37, 44), to 2000 mg paracetamol (39) and 2400 mg ibuprofen (43) a day. One study permitted the 
use of hydrocodone/paracetamol (5mg/325mg) up to two tablets a day during the first two weeks of 
titration (44). Two studies allowed the use of paracetamol, aspirin or low-dose NSAIDs but did not 
specify the maximum dosage allowed (36, 48). One study of transdermal fentanyl allowed oral 
transmucosal fentanyl rescue doses (400 mcg/dose, no daily maximum) (46), whilst another 
transdermal fentanyl study allowed the use of short-acting oral opioids (name, dose, and daily limit 
unspecified) as rescue medications (50).  
 
Homogenous diagnostic subgroups were the target samples of the majority of the studies (n=14; 
70%). Of these, six included patients with chronic low back pain (33, 36, 37, 43, 44, 50), six with chronic 
osteoarthritis knee or hip pain (35, 38-40, 42, 49), one with chronic neck pain (41), and one with chronic 
postherpetic neuralgia (34). However, inclusion criteria varied in terms of the required level of pain 
severity, intensity, duration, and prior treatment history (Table 1). Only two studies (16.7%) used the 
presence of sleep disturbances as an inclusion criterion (37, 49) and one of these specifically screened 
out patients with sleep apnoea (37). These two studies were the only ones investigating the effect of 
opioid therapy on sleep physiology using objective measures of sleep (overnight polysomnography; 
PSG) (37, 49). The remaining studies primarily focused on the efficacy of opioids in providing pain 
relief, with sleep as one of the secondary outcome measures. These studies used self-reports (e.g., 
questionnaires, ratings, diary) to measure sleep, with eleven relying on non-validated single-item 
ratings to assess sleep quality (33-36, 39-42, 45, 46, 48).  
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3.3 Risk of bias in included studies 
Summaries of the risk of bias assessment are presented in Figures 2 and 3. Briefly, by category of 
bias, the majority of the studies were judged to be of either “unclear” or “high” risk of selection bias 
due to inadequate random sequence generation (n=10 studies; 56%) or allocation concealment (n=12 
studies; 67%); performance bias due to insufficient blinding of participants and personnel (n=15 
studies; 83%); detection bias due to insufficient blinding of outcome assessment (n=14 studies; 78%); 
attrition bias due to incomplete outcome data (n=14; 78%); reporting bias due to potential selective 
reporting (n=18; 100%); and other bias due to potential conflicts of interest (n=11 studies; 61%). 
Detailed assessment results are provided in supplementary materials. 
 
(Insert Figures 2 and 3 about here) 
 
3.4 The effect of opioid therapy on objectively measured sleep physiology and architecture  
Objective sleep measures from the only two PSG studies suggested that the use of opioid therapy is 
associated with a mix of possible positive and negative changes in sleep physiology and architecture. 
In their randomised cross-over trial comparing the efficacy of extended-release hydromorphone 
morning versus evening dose following a no treatment baseline and an immediate-release 
hydromorphone open-label run in, Webster et al. (37) observed a significant within-group increase in 
the apnoea-hypopnoea index (AHI) index in the 15 chronic low back pain patients tested; from 12.1 
at baseline without opioids to 17.1 when on extended-release hydromorphone (evening dose). This 
increase raised the level of apnoea from “mild” to “moderate”, highlighting that the introduction of 
opioid therapy of a mean dose of 40 MME was associated with a greater number of apnoea and 
hypopnoea events during sleep and hence impaired respiratory function. Such change in AHI was 
accompanied by a statistically but not clinically significant increase in the central sleep apnoea (CAI) 
index (from 0.9 at baseline to 1.8 when using extended-release opioid treatment in the evening) and 
reduction in average blood oxygen level as measured with pulse oximetry (from 92.8% at baseline 
without opioids to 92% when on extended release hydromorphone or 91.7% when on immediate 
	 14 
release hydromorphone) (37). However, positive changes were also reported in the same study in the 
form of a significant reduction in leg and body movements during sleep, in wake time after sleep 
onset, and in sleep efficiency (37). These changes were statistically but not clinically significant when 
comparing the use of no opioid at baseline with the use of hydromorphone regardless of the timing 
of dose and release method, except for sleep efficiency for which a statistically significant difference 
was only observed between baseline and the use of extended release hydromorphone (evening dose).  
 
In a separate non-randomised single-treatment placebo-lead in study of 34 patients with chronic 
osteoarthritic knee or hip pain by Rosenthal et al. (49), there was equivocal evidence of possible 
improvements in sleep efficiency and total sleep time after introducing low (30 MME) to medium 
(60 MME) doses of morphine. Intriguingly, such improvement was only statistically significant when 
compared with measurements obtained while the patients were on their original non-opioid 
analgesics, but not with measurements obtained during the washout period when the patients were 
not using any pain medication at all. Moreover, the use of opioid therapy reduced REM sleep latency, 
from 113.9 min when the patients were using their original pain medications, to 84.1 min after the 
patients had gone through a 5-day washout period, and to 68.5 min at day 13 or 14 of the morphine 
sulphate treatment.  
 
In summary, the available objective PSG findings based on low to medium opioid doses indicate that 
there are both risks and benefits associated with the use of opioid therapy. Whilst CNP patients could 
experience calmer sleep with less body and leg movements as well as fewer night time awakenings, 
these may occur at the risk of an increase severity in SDB and a much shortened REM latency. 
Intriguingly, neither of these PSG studies found the introduction of opioid therapy in CNP patients 
being associated with a reduction in SWS and REM and an increase N2 sleep as commonly seen in 
studies with healthy, pain-free volunteers (26).  
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3.5 The effect of opioid therapy on self-reported sleep  
A number of validated and non-validated self-reported measures were used to assess subjective 
aspects of sleep. The validated measures included the Medical Outcomes Study Sleep Scale (MOS 
Sleep Scale) (51, 52), the Pittsburgh Sleep Quality Index (PSQI) (53) , the Epworth Sleepiness Scale 
(ESS) (54), and the Verran and Snyder Halpern Scale (VSH) (55). Non-validated measures mainly took 
the form of single-item or multi-item ratings of sleep quality and quantity using different word 
anchors, numerical or analogue scales, and operational definitions of the concepts. Given the variety 
of measures used, below we report the findings by type of measure in an attempt to integrate results 
across studies. 
 
Three studies used the MOS Sleep Scale, or a modified version of it, to assess overall sleep quality 
(37, 38, 44). Findings of two of these studies evaluating the efficacy of hydromorphone converged to 
suggest an improvement in sleep disturbance, snoring, awakening due to shortness of breath or 
headache, when comparing the opioid therapy with a baseline without opioids (37, 38). However, a 
study evaluating the efficacy of buccal buprenorphine found no differences in the pre-post treatment 
change in MOS sleep score between the buprenorphine and placebo groups (44).  
 
Further disparities in results were observed between studies measuring sleep-related parameters using 
the PSQI, ESS, and VSH. Rauck et al. (43) reported a significant improvement in PSQI score 
suggesting better overall sleep quality after 8 weeks of morphine sulphate or oxycodone treatment 
compared to baseline, with the former treatment group showing greater improvement on PSQI than 
the latter. However, score data were not provided in the paper for further examination. Rosenthal et 
al. (49), on the other hand, noted a significant increase in ESS score suggesting greater daytime 
sleepiness after 14 days of morphine sulphate treatment. Simpson et al. (50) found no significant 
improvement in overall sleep quality as measured with the VSH following a 1-month long treatment 
	 16 
with transdermal fentanyl, although one of the eight subscales (VSH1) indicated a reduction in the 
number of awakenings during the night compared to baseline. 
 
Three of the studies included questionnaires that contained a single item about sleep, respectively the 
European Organisation for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-
QLQ-30 (56)), the SPAASMS score card, which contains one item for each of the following: S- Score 
for pain, P- Physical activity levels, A- Additional pain medication, A- Additional Physician/ER 
Visits, S- Sleep, M- Mood, S- Side effects (48), and the Multidimensional Pain Inventory (MPI (57)). 
Using the EQRTC-QLQ-30 item, Fredheim et al.(47) documented significant improvements in the 
sleep difficulties and fatigue ratings after up to 9-month of treatment with oral methadone. Using the 
SPAASMS item, Mitra et al. (48) reported no change in sleep quality rating at 12-month of treatment 
with either transdermal buprenorphine or fentanyl. Using the MPI item, Raja et al. (34) noted a small 
reduction in sleep disturbance rating following opioid therapy but not placebo treatment.    
 
Eleven studies involved the use of non-validated single-item rating scales to measure sleep quality 
(33, 35, 36, 39-42, 45, 46, 48, 49). All but two studies (33, 48) reported higher sleep quality ratings, reduced sleep 
disturbance frequency, longer sleep hours, or increased incidence of patients reporting sleep 
improvement or better sleep quality following opioid treatment and/or compared with placebo. 
Contradictory findings were noted between the two studies that asked participants to report their sleep 
duration at different phases of treatment. The mean number of hours of sleep reported increased from 
6.1hr at baseline to 6.6hr following 14 days of treatment with morphine sulphate (49), but no 
differences were found following different oxycodone treatment regimens with or without morphine 
sulphate (33). Similar inconsistency was observed within a study that used 2 single-item rating scales 
to measure sleep quality (40). Whilst the proportion of patients reporting “mild or moderate problem 
sleeping” did not separate the transdermal fentanyl group from the placebo group, the percentage of 
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people reporting “severe insomnia” was nearly 3 times higher in the transdermal fentanyl than the 
placebo groups. 
 
Only one study collected self-reported sleep data using a daily sleep diary (37), offering the opportunity 
to examine individual perceived sleep parameters such as sleep onset latency, total sleep time, number 
and length of awakening after sleep onset, sleep efficiency, and even subjective evaluations of how 
“enjoyable” sleep was the previous night. However, this study only required participants to keep a 
daily diary during the treatment periods, but not at pre-treatment baseline. Comparisons could thus 
only be made between different types of opioid release-method (immediate vs. extended) and timings 
of dose (morning vs. evening), which had no significant effects on any of the sleep diary parameters.  
 
There was no clear pattern from the findings suggesting that sleep outcomes were associated with the 
dose and type of opioid tested. By dose, all but one trial (33) with low-dose opioids had positive sleep 
outcomes (35-37, 39, 42, 49). Just over half of the trials that used medium-dose opioids were successful (34, 
43, 45), whilst the remaining were not (49, 50). Of the three trials that used high- to very high-dose opioids, 
one had positive self-reported sleep outcomes (46) but mixed results were reported in the other two (40, 
47). By type, trials that tested hydromorphone (37, 38), codeine (42), tramadol (35, 36, 39), oxycodone (33, 38, 
41, 43) and morphine (34, 43, 45, 49) tended to have positive sleep outcomes, whilst inconsistent results 
were returned for trials that tested fentanyl (40, 46, 48, 50), methadone (34, 47), and buprenorphine (39, 44, 48). 
 
3.7 Reported sleep-related AEs and attrition associated with opioid therapy 
Presented also in Table 2 were the sleep-related AEs associated with the introduction of opioid 
therapy.  “Somnolence”,  “sedation”, “drowsiness” and “sleepiness” were the most frequently 
reported. Other sleep-related AEs reported included “insomnia” (36, 40), “nightmares” (33, 48) and 
“fatigue” (36, 37, 39, 44). “Severe sedation and unresponsiveness” was reported as a serious AE in one 
study that used morphine sulphate (49). 
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The median attrition rate across the studies was 41.85%, with AEs being the first cause. Other most 
prominent causes of attrition were lack of efficacy, protocol violation, consent withdrawal and lost to 
follow-up. Whilst most studies did not specify the nature of the AEs cited as reasons for attrition, 
“somnolence” and “sedation” were listed as major causes of patient attrition in three studies that used 
transdermal fentanyl (46, 50) and methadone (47).  
 
In the only study that specifically screened for sleep apnoea, two of the 22 participants enrolled were 
excluded during the titration phase due to “severe sleep apnoea” and a further patient (of the 15 who 
started treatment) had to be excluded during the treatment phase due to an AHI index >30, an indicator 
of severe sleep apnoea (37). This level of attrition due to impaired respiratory function highlights the 
importance to screen for symptoms/vulnerabilities of sleep apnoea before administering any opioid 
therapy, and continued monitoring during ongoing treatment.  
 
In summary, the balance of the evidence from self-reported sleep measures appears to suggest an 
improvement in overall sleep quality under low to medium dose opioid therapy. However, such an 
improvement is not consistently detected across studies and may be accompanied by an increase in 
excessive daytime sleepiness.  
 
3.6 Exploratory meta-analysis 
Data available from 5 RCTs, involving a total of 444 person-count in the opioid therapy group, were 
used to perform an exploratory meta-analysis (33-37). As evident in Figure 4, the overall effect of opioid 
therapy on sleep quality was found to be significantly better than control or non-opioid therapy 
(Z=3.73, p=0.0002). The size of the effect was 0.36 (95% CI 0.17, 0.54), which is a small effect size. 
Heterogeneity between the studies was not detected as an issue (I2=35%), despite the range of study 
designs and sleep quality measures used. Visual inspection of the forest plot suggested that the 
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Webster study (37) contributed most to the effect. Since this study was also the only study in this 
analysis that set out to examine the effect of opioid therapy on sleep, a sensitivity analysis was carried 
out by without the Webster study (37). This reduced the level of heterogeneity to 0%. The effect of 
opioid therapy on sleep quality attenuated to 0.27 (95% CI 0.13, 0.40) but remained statistically 
significant (Z=3.73, p=0.0002). Examination of the asymmetry of the funnel plot (Figure 5) revealed 
possible biases with studies of greater precision producing smaller or no effect.   
 
(Insert Figures 4 & 5 about here) 
4. Discussion  
Our synthesis of 18 opioid treatment studies aimed to clarify the effect of opioid therapy on sleep 
architecture and sleep quality in patients with CNP. The size of the corpus was smaller than expected, 
considering the high prevalence of opioid therapy (58, 59). Most of the studies reviewed had sleep as a 
secondary outcome. Only two studies had sleep as the primary treatment outcome, measuring not 
only self-reported changes in sleep experience but also more subtle alterations in sleep architecture 
and physiology. However, both of these studies had small sample sizes and were exposed to more 
than one source of risk of bias. With several initiatives that call for more comprehensive assessment 
in pain trials to cover – beyond pain – related outcome domains important to patients (13, 58, 60, 61), there 
is a trend for newer opioid trials to report treatment associated changes in sleep and fatigue (62). It is 
hopeful that a larger and stronger body of research will be available for analysis in future revisions 
of this systematic review.  
 
For now, based on the studies identified for the current review, the balance of the evidence suggests 
that the use of opioid therapy in CNP with short to medium term outcomes (max=12 months) is 
associated with a report of improved overall sleep quality. That said, it must be emphasised that there 
were inconsistencies in the direction and strength of the sleep improvement findings within and across 
studies. Meaningfulness of the sleep improvement was not always discussed, even in studies using 
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validated instruments such as the PSQI and MOS-Sleep Scale that have established score 
interpretation and cut-offs (37, 38, 43, 44). Whilst statistical significance of such improvement was found 
in the exploratory meta-analysis, the magnitude of change was small (SMD = 0.36), such that there 
is 60% chance that a person randomly picked from the opioid therapy group would have a better 
overall sleep quality rating than the control group. If we assume that the control group have 10% 
clinically significant outcome, we need to treat 12.8 more people in order to have one more clinically 
significant improvement in overall sleep quality in the opioid group. The exploratory meta-analysis 
was conducted with a selected subset of data, restricted by the heterogeneity in trial design, the type 
and dose of opioids used, and outcome measures used across studies. It only served as a broad 
estimation of the possible improvement in self-reported sleep quality following opioid therapy. A 
high level of caution is required for the interpretation of the results, given the potential publication 
bias towards positive findings with studies of greater precision producing smaller or no effect. 
 
We cannot tell from the available evidence whether the reported improvement in sleep quality 
differed by the type or dose of opioid used, although we note that trials testing low-dose opioids 
tended to have positive self-reported sleep outcomes (35-37, 39, 42, 49) whereas no improvement in sleep 
quality was found in all of the three studies that used transdermal or buccal buprenorphine (39, 44, 48) 
and in three of the four studies that used transdermal fentanyl (40, 48, 50). The majority of the studies 
used low- to medium-dose opioids. Outcomes in the very high- (47) and high- (40, 46) dose opioid trials 
did not appear superior to those of trials that used opioids in the mediume- to low-dose range, as the 
proportion of studies reporting a positive impact on sleep quality was identical (67%) across both 
ends of the dose spectrum.  
 
The limited PSG data suggest that opioid therapy may have mixed effects on objectively measured 
sleep parameters (37, 49). Neither of the PSG studies replicated the sleep disruptive effects (e.g., reduced 
SWS and REM and increased N1 and N2 sleep) commonly observed following the acute 
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administration of opioids to healthy pain-free volunteers (16, 63). Such inconsistent findings may be 
attributed to the differences in sample characteristics and their interactions with the opioids tested, 
although future research is required to verify this speculation. Whilst positive changes were observed 
in the reduction of leg and body movements, minutes of night time awakenings and hence an increase 
in sleep efficiency, no significant improvements were seen in other important parameters associated 
with better sleep quality, e.g., (shorter) sleep onset latency, (reduced) number of arousals, (increased) 
N3 or SWS. It must also be emphasised that, in both trials that had PSG data, more than half of the 
reported parameters were still within the clinical range at the end of the treatment period (e.g., sleep 
efficiency < 85%; sleep onset latency >30min; wake after sleep onset >30min (37)). Only one of the 
two trials reported an increase in total sleep time (49). In this trial (49), REM latency was also shortened 
by an average of 16 minutes from baseline to after the opioid therapy. The clinical significance of 
this finding is unclear as it may only be an artefact of a REM rebound due to pain relief. It is also 
unclear whether the shortened REM latency was experienced positively or negatively by the patients. 
REM sleep plays an important role in emotion regulation and affective memory consolidation. A 
shorter REM latency and an increased REM intensity have been associated with a range of psychiatric 
symptoms and disorders (e.g., depression, mania, suicidality (64-68)). These findings together present 
a paradox, as the patterns of changes in objectively measured sleep parameters neither correspond 
with the self-reported improvement in sleep quality nor do they present a picture of normal sleep 
following opioid therapy.  
 
Although not the focus of the present review, the only selected study that screened out patients with 
sleep apnoea showed that opioid therapy increased the mean number of apnoea events (measured by 
the AHI score) from the ‘mild’ to the ‘moderate’ level in patients supposed to be ‘safe’ to initiate 
treatment (37). Notably, of the 14-strong ‘safety sample’, three further patients had to be excluded 
during the treatment phase of the study: two in the titration phase because of “severe sleep apnoea” 
and one due to “unacceptably high AHI score during the final sleep study” (37). These findings 
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underline the risk of opioids-induced SDB as established in previous reviews (14, 16, 69). The respiratory 
depression effect was particularly strong for extended-release opioid administered in the evening, 
compared to a morning administration and to the immediate-release formulation (37). That said, it must 
be noted that acute use of low-medium dose of morphine does not always worsen SDB, even in high-
risk patient samples of pre-existing OSA or on methadone maintenance treatment (27, 70).  
 
On the issue of safety, there was little information on the AEs’ definition, threshold for report and 
impact on the patient’s functioning. The most frequently cited sleep-related AEs and reasons for 
attrition across the reviewed studies were “somnolence”, “sedation”, “drowsiness” and “sleepiness”, 
suggesting the opioids acted as a double-edge sword for patients when arousal-altering effects were 
non-specific in timing. Two recent studies have shed new light on the nebulous mechanisms 
underpinning the arousal-altering function of opioids. Montandon et al. (71) have shown in a paediatric 
population that preoperative morphine induced a sedative state marked by reduced frontal high-
frequency EEG power in the beta range and reduced frontal-occipital beta activity coherence. This 
may be linked to the loss of sustained attention associated with the use of opioids. In a separate study, 
reductions in beta power and coherence were found to be strongly, positively correlated with 
depression in respiratory rate induced by morphine, suggesting that the severity of respiratory 
depression is associated with reductions in cortical arousal (72).  
 
The discussion above must be considered in light of the limitations of the studies reviewed, with 25% 
being very small (n<50) and 33% non-RCTs. Amongst the RCTs, a specific concern is concerned 
with the randomised-withdrawal enriched-enrolment design, where only drug-responders are retained 
in the trial, which could inflate therapeutic effects. As there was no control in the analyses for the 
effect of rescue medications, one could argue the trials that authorised such rescues were actually 
examining the combined effect of opioids and non-opioids analgesics, rather than the effect of opioids 
on their own. The overall risk of bias assessment revealed that all studies were at ‘high’ risk of bias, 
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except 3 that were considered of ‘unclear’ risk. The risk of bias assessment was conservative, 
avoiding assumptions in the absence of information, leading to markings of ‘unclear’ risk for studies 
that provided insufficient details. Hence, the judgement of ‘unclear risk’ does not preclude the 
possibility of a high risk of bias in studies with thin reporting. Clearly, there is much room for future 
opioid trials to improve on their conduct, reporting, and on the inclusion of more and better sleep 
outcomes.  
 
In terms of future research directions, aside from striving for better-quality trials with longer follow-
up periods, two interesting observations gave us some food for thought:  
 
First, there is poor concordance in the direction of change between the self-reported and objective 
findings of sleep. Patients can report an improvement in their sleep quality when the severity of SDB 
has increased and without significant changes in important parameters reflecting deeper and more 
restorative sleep. Patients’ reported improvement of sleep quality can also be accompanied by a 
reported increase in daytime sleepiness, which is not what we would normally expect with night time 
sleep improvement. This phenomenon is perplexing, and it is more than just the subjective-objective 
discrepancy between people’s perception of sleep and technologies’ estimation of sleep (73-77). Here, 
the mismatch in perception is across sleep parameters. We hypothesise that it may be linked to how 
people reconcile an array of varying, ambiguous bodily information in order to make a categorical 
judgment whether sleep has improved or not after opioid therapy. If we conceptualise the 
phenomenon this way, the sleep quality judgment can be understood as a decision-making process 
whereby people will have to combine all information that they are aware of to make a single response. 
This hypothesis is supported by our recent work demonstrating that sleep quality is indeed a 
judgement that can be influenced by different information, including memories from the pre-sleep 
period, feelings upon-awakening and next day events (78). People put more weight on total sleep time, 
feeling refreshed upon waking and mood during the day than on other factors when they make their 
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judgement of sleep quality (78). We suspect similar information processing is required when patients 
are being asked to decide whether the new opioid therapy has improved their sleep quality. The 
decision could be challenging, and much more variable over time, if the opioid therapy has resulted 
in mixed improvements (e.g., fewer awakenings in the night, just about the same hours of sleep, but 
greater drowsiness during the day). Also, they may not be aware of higher number of apnoea events, 
since they may be too brief to be detected, processed, and/or registered in memory. It raises the 
question whether in future trials where PSG assessments are carried out, patients should be explained 
their sleep studies’ results before expressing a judgement on the drug’s effect on sleep.  
 
Second, many patients believe pain is the main cause of their sleep problems, and as a result, they 
think getting rid of the pain is a prerequisite to restoring a normal night’s sleep (79). Accordingly, the 
pain-reliving and hypnotic properties of opioids do make them an attractive option for chronic pain 
patients with concomitant sleep disturbances (80). Does the use of opioid therapy bring about better 
sleep through pain reduction? This question will require future trials with more frequent assessments 
of both pain and sleep throughout the treatment process, to allow for a proper mediation analysis. 
Although, we note from our data that 5 of the 18 (27.8%) reviewed studies found no significant 
improvement in overall sleep quality or day-to-day reports of sleep experience even when opioids 
demonstrated benefits on pain (33, 40, 44, 48, 50). Therefore, it appears that pain reduction is not a sufficient 
condition for sleep to improve. Even if an indirect effect from reduced pain to improved sleep exists, 
the strength and longevity (both across development of tolerance or following washout) of this effect 
needs to be determined. If the indirect therapeutic benefit of opioids on sleep is small, short-lived, 
and/or not guaranteed, such information should be made available in prescription guidelines and 
shared with patients when making a treatment decision. Such a suggestion would be in line with the 
recommendation that deciding whether or not to initiate/stop opioid therapy should be based on an 
informed, collaborative risk/benefit analysis between patients and physicians (1, 8, 10, 81, 82). Alternative 
interventions to promote sleep should also be offered; there is good evidence for the efficacy of 
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cognitive-behavioural interventions for insomnia in this population (83). New generations of hybrid 
interventions that target simultaneously pain and sleep issues, both in secondary and primary care,  
are being developed (84-87). Given the bidirectional link between sleep and pain, the effects of these 
interventions on sleep and indirectly on pain and down the line on opioid-sparing should be studied. 
 
In closing, the current systematic review has identified a set of papers with relevant outcomes 
regarding the effect of opioid therapy on sleep quality and sleep architecture in CNP patients. It 
extends our understanding from the drug’s respiratory depression effect in healthy individuals to the 
potential risks and utility of opioid therapy for CNP patients with sleep disturbances. Whilst the 
narrative synthesis and the exploratory meta-analysis of a subset of data both suggest that the use of 
opioid therapy is associated with an overall report of sleep quality improvement, such an 
improvement is not consistently replicated across studies or substantiated by improvements in sleep 
parameters linked to deeper and better-sleep quality. Moreover, the improvement may be 
accompanied by undesirable side effects and increased daytime sleepiness that contradict with the 
very idea of improved sleep quality. We are also painfully aware of the methodological limitations 
of the studies reviewed; their exposure to different sources of biases has heightened the risk of result 
inflation. To many patients with CNP, improved sleep is a top priority when evaluating the 
performance of a new drug and non-drug intervention. If we were to advance our current 
understanding of the opioid-sleep relationship, future trials need to be designed with this 
interdisciplinary question in mind such that validated measures of sleep can be incorporated as an 
outcome measure alongside pain. Like pain, sleep is a multidimensional experience. It would be 
important for future opioid trials to take a more nuanced approach when assessing the effect of opioids 
on sleep. Different kinds of sleep measures reflect different dimensions of sleep, and there are 
scientific and clinical reasons to go for a combination of both self-reported and objective measure of 
sleep. This research approach should be applied to future studies examining the effect of new opioid 
therapy on CNP, as well as future trials looking into opioids tapering amongst patients on high doses 
	 26 
but are no longer deriving therapeutic benefits (88, 89). This would be a timely item on the research 
agenda riding on the emerging priority to reduce opioid use against the national/international 
epidemic of misuse/overdose (7, 8, 58, 59, 90).  
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Practice Points:  
1. Use a combination of validated self-reported measures (questionnaire, sleep diary, spouse 
report) and objective tools (actigraphy, PSG) for sleep assessment.  
2. Inform patients and discuss the effect of opioids on sleep and daytime sedation when 
considering opioid therapy. 
3. If a sleep study was performed before and after opioid therapy, explain the results to patients 
in full so they are aware of changes to their sleep physiology associated with the drug. 
4. Offer alternative sleep interventions for CNP patients who seek opioid therapy as a sleep 
aid.  
5. Routinely assess SDB before, during, and after opioid therapy, even for patients with low 
risk of sleep apnoea. 
 
Research Agenda:  
1. Future opioid trials should include sleep as an outcome, using well-validated sleep quality or 
architecture measures. 
2. Future sleep intervention trials for CNP should include pain and analgesic (including opioid) 
use as outcomes.  
3. Developing a consensus as to which sleep measure(s) should be recommended as core 
outcome measure(s) in RCTs.  
4. To identify the PSG signature of opioids both in terms of macro- and micro-sleep 
architectural changes. 
5. To examine the effect of long-term opioid use (>12 months), opioid switching and opioid 
tapering on sleep. 
6. To investigate the potential opioid-sparing effect of sleep intervention for CNP. 
7. To identify the biological, psychological, and contextual factors that influence people’s drug 
preference and categorical judgment of sleep quality following opioid therapy.  
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Figure	2.	Risk	of	bias	of	all	included	studies.	Review	authors'	judgements	about	each	risk	of	bias	item	presented	as	percentages	across	all	included	studies.	Other	bias	refers	to	potential	conflicts	of	interest.				
	
Figure	3.	Risk	of	bias	summary.	Review	authors'	judgements	about	each	risk	of	bias	item	for	each	included	study	[with	their	respective	reference	number]	are	presented.	Other	bias	refers	to	potential	conflicts	of	interest.		
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Figure	5.	A	funnel	plot	of	studies	presented	in	Figure	4.	Each	circle	represents	an	entry	in	the	forest	plot.	The	x-axis	represents	the	study	results	as	measured	with	standardised	mean	differences	(SMD).	The	y-axis	represents	study	precision	as	measured	with	standard	error	(SE)	of	SMD.			
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ith	5	x	100m
m
	VAS	(never	to	alw
ays)	&
	a	final	item
:	
no.	of	hrs	of	sleep
Com
posite	Sleep	Score	-	sum
	of:	
			trouble	falling	asleep;
			needed	pain	m
edications	to	sleep;	needed	sleep	m
edication	to	sleep
			aw
akened	by	pain	at	night;		aw
akened	by	pain	in	the	m
orning
Authors,	yr	
[ref.];country
Study	design	
O
pioids	used
Participant	group
Age	(yr)										
at	baseline	
Fem
ale	(%
)								
at	baseline
Received	Rx	
(n)
Finished	Rx	
(n)
Sleep	m
easure(s)
Vorsanger	et	al.,	
2008	[36];	USA	
Random
ised-w
ithdraw
al
Open-label	lead-in
Double-blind
Placebo-controlled
Parallel-group
M
ulticentre		
12	w
eeks
Tram
adol,	ER
vs.
Placebo
CLBP	
w
ith	m
oderate/severe	pain	
despite	daily	treatm
ent	w
ith	a	
NSAID,	acetam
inophen,	opioid	
analgesic,	COX-2	selective	
inhibitor,	and/or	m
uscle	relaxant	
for	at	least	60-90	days	prior	to	
study
47.8
50
619
241
Q
uality	of	sleep	
Self-reported	rating:	overall	quality	of	sleep	on	100-m
m
	VAS	scale;	0	=	very	poor,	100	=	
excellent
W
ebster	et	al.,	2015	
[37];	USA
Random
ised
Open-label	run-in
Double-blind
Placebo-controlled	(w
ithin	arm
)
Crossover	trial	
2x	14	days
Titration	phase:
Hydrom
orphone,	IR	
Study	treatm
ent	phase:	
Hydrom
orphone,	ER	vs.	placebo
Q
AM
:	08:00-10:00	intake	of	active	
m
edication
vs.	
Q
PM
:	20:00-22:00	intake	of	active	
m
edication
CLBP	
w
ithout	sleep	apnoea,	using	long-
term
	opioid	therapy	or	qualified	
for	around-the-clock	opioid	
therapy	for	an	extended	am
ount	
of	tim
e
44.4
60
22
12
Polysom
nography
1	night	of	recording	for	each	of	4	sleep	studies.	AASM
	Scoring.	Param
eters	exam
ined:
			AHI;		Sleep	onset	latency	;	Sleep	efficiency
			M
in.	of	w
ake	tim
e	after	sleep	onset;		M
in.	in	stages	1-4	sleep
			REM
	sleep;		Respiratory	events	
			No.	of	arousals	from
	sleep	;		No.	of	leg	m
ovem
ents	
			Body	position	changes	during	sleep
M
odified	M
edical	O
utcom
es	Study	Sleep	Scale	#	(m
odifications	N/S)
6	dom
ains	reported:		
			Sleep	disturbance;	Snoring;	Aw
akening	short	of	breath	or	headache;	Sleep	quantity
			Daytim
e	som
nolence;	Sleep	problem
	index
Sleep	Diary
Com
pleted	daily,	including	the	follow
ing:
		Sleep	onset	latency;		Total	sleep	tim
e;	How
	enjoyable	w
as	your	sleep	last	night?
		No.	of	aw
akening	after	sleep	onset;		W
ake	tim
e	after	sleep	onset	
		Sleep	efficiency;		How
	w
ell	do	you	feel	this	m
orning?
		
Notes.	Included	studies	are	presented	by	lead	author's	alphabetical	order.	
N/S	=	Not	specified.+	=	And.	Vs.	=	Versus.	T	=	Titration.	Rx	=	Treatm
ent.	Yr	=	Year.	M
th	=	M
onth.	W
k	=	W
eek.	Hr	or	h	=	Hour.	M
in	=	M
inute.	No.	=	Num
ber.	U/C	=	Unclear;	cannot	w
ork	out	the	total	num
ber	of	patients	com
pleting	treatm
ent	due	to	reporting.	Alt.=	Alternative
✜	M
edian	age	reported.	§	Taking	into	account	a	subsequent	site	exclusion	due	to	NIDPOE=	Notice	of	Initiation	of	Disqualification	Proceedings	and	Opportunity	to	Explain	by	the	US	Food	and	Drug	Agency's	Division	of	Scientific	Investigation.	♮	Based	on	calculation	subtracting	the	
num
ber	of	discontinuation	from
	the	stated	sam
ple	of	the	respective	study	phase	in	the	flow
	diagram
,	but	w
e	noted	that	the	num
bers	in	flow
	diagram
	did	not	add	up	and	w
ere	inconsistent	w
ith	the	num
bers	provided	in	the	text.	#	Validated	sleep	questionnaire
Opioids:	unless	specified	otherw
ise,	m
edications	are	oral,	ER	=	Extended	release	(including	Controlled	release,	Slow
	release,	Sustained	release)	,	IR	=	Im
m
ediate	release,	Q
AM
=	m
orning	dosing,	Q
PM
:	evening	dosing.	
AASM
	=	Am
erican	Academ
y	of	Sleep	M
edicine	(2007	scoring	m
anual).		AHI	=	Apnoea-hypopnoea	Index.	CLBP	=	Chronic	low
	back	pain.		CNP	=	Chronic	non-m
alignant	pain.	EORTC	Q
LQ
-C30	=	European	Organisation	for	Research	and	Treatm
ent	of	Cancer	(EORTC)	Q
LQ
-C30	
questionnaire.	HRQ
oL	=	Health-related	Q
uality	of	Life.	OA	=	Osteoarthritis.	R&
K	=	Rechtschaffen	&
	Kales.	REM
	=	Rapid	eye	m
om
vem
ent.	SPAASM
S	=	On	this	score	card,	treatm
ent	progress	w
as	studied	across	seven	dom
ains:	score	of	pain	(S),	physical	activity	(P),	additional	rescue	
m
edication	(A),	additional	general	practitioner/em
ergency	departm
ent	(GP/ED)	visit	(A),	sleep	quality	(S),	m
ood	(M
),	and	side	effects	of	pain	m
edication	(S).		VAS	=	Visual	analogue	scale.	
Table	2.	A	Sum
m
ary	of	Relevant	Findings	of	Included	Studies
Authors,	yr	
[ref.];country
O
pioids	regim
en
Daily	dose	in	M
M
E
Attrition
Reason/tim
ing	(n)
Adverse	events/Serious	
adverse	events
Sleep-related	AE/SAE		(n)
Sleep	outcom
es
Pain	outcom
es
Risk	of	
bias^
Adam
s	et	al.,	2006	
[45];	USA
M
orphine	sulphate,	
ER		
M
ean	daily	dose:
Baseline	:	30	m
g		
M
th	1:	66	m
g
M
th	3:	74	m
g
Start	dose:	
30	M
M
E
M
th	1	m
ean:
66	M
M
E
M
th	3	m
ean:
74	M
M
E
Total:	282/491	patients	(57.4%
)	did	not	
take	the	drug	for	the	total	planned	
duration.	171	(34.8%
)	discontinued	
treatm
ent	drug	prem
aturely.
Reasons	for	discontinuation	at	Baseline,	
M
th	1-2,	and	M
th	3:
TOTAL	(21,	117,	33)
Side	effect	(15,	56,	10)
Persistent	pain	(3,	18,	11)
Drug	costs	(1,	18,	5)
No	longer	needed	(1,	42,-)	
Physician	decision	(-,	2,	2)
Other	(4,	31,	7)
Total:		Opioid-related	AEs	-	
N/R;	25	SAEs	-	2	w
ere	
considered	drug-related	
requiring	hospitalisations	for	
vertigo,	nausea	and	vom
iting
Sleep-related	AE/SAE:	N/R
M
ulti-item
	sleep	assessm
ent	(Self-report)
Com
posite	Sleep	Score	significantly	reduced	from
	5.73	at	
baseline	to	4.96	at	M
th	3.	
Significant	im
provem
ents	from
	baseline	to	M
th	3	w
ere	
observed	for	2	of	the	4	individual	VAS	item
s	reported;	
aw
akening	in	the	m
orning	and	need	for	sleep	m
edication.	 M
ean	one-day	pain	score	(0-10	VAS;	0=no	pain;	10=w
orst	
possible	pain	you	can	im
agine)	(self	report)
significantly	decreased	from
	7.83	at	baseline	to	5.84	at	
M
onth	3
Pain	control	rating	(self	report)
Of	the	149	patients	w
ho	took	the	drug	throughout	the	
study,	the	proportion	endorsing	"pain	som
etim
es	
controlled"	increased	from
	16%
	at	baseline	to	28%
	at	M
th	
3,	but	there	w
ere	no	significant	changes	in	the	proportion	
of	participants	endorsing	the	rest	of	the	categories	"pain	
alw
ays	controlled".	"pain	better	but	never	gone",	or	"pain	
not	w
ell	controlled".	
High
Collado	&
	Torres,	
2015	[46];	USA	
Transderm
al	fentanyl	
(TTS)
Start	dose:12	μg/h		
Increases	by	25	μg/h	
M
ax	125	μg/h
and	
RM
:	O
ral	
transm
ucosal	
fentanyl	citrate,	IR		
(OTFC)		400	μg/dose	
as	needed																													
Start	dose:
30	M
M
E
M
th	1	m
ean:
104	+	RM
	160	M
M
E
	M
th	3	m
ean:
118	+	RM
	120	M
M
E
M
th	6	m
ean:
127	+	RM
	105	M
M
E
M
ax	dose:	
300	M
M
E
Total:	12	/215	patients	(5.6%
)	
discontinued	due	to	side	effects
Reasons	for	discontinuatoin	at	M
th	1,	
M
ths	2-5,	and	M
th	6:
M
th	1	
Nausea/vom
iting	(7,-,-)
Som
nolence	(1,	1,	1)
Derm
atitis(-,1,-)
Total:	270	records	in	M
th	1;	
172	records	in	M
th	6
Sleep-related	AE/SAE:	
M
th	1	
Som
nolence	(86)
M
th	6
Som
nolence	(85)
Q
uality	of	sleep	(poor,	if	<6	consecutive	hrs	of	night	
sleep)(self	report)
%
	of	patients	(n=215)	w
ith	'poor	quality	sleep'	decreased	
from
	99%
	at	baseline	to	2.8%
	at	the	end	of	the	study	
(after	6	m
ths	of	treatm
ent)
M
ean	pain	intensity	0-10	VAS	score	(self	report)
decreased	from
	9.9	(SD=0.35)	at	baseline	to	2.1	(SD=2.05)	
at	the	end	of	the	study	
%
	of	patients	w
ith	inadequate	pain	control	(pain	intensity	
VAS>4)	decreased	from
	100%
	at	baseline,	to	2.3%
	at	the	
end	of	the	study
High
Fredheim
	et	al.,	
2006	[47];	Norw
ay
Baseline	treatm
ent:	
O
ral	SR	m
orphine	
M
ean	202	m
g/day
Sw
itch	over	course	of	
3	days	to	m
ethadone		
Study	drug:	O
ral	
m
ethadone		
Start	dose:	3x	5	
m
g/day	
Increases	by	5	m
g	
over	1	w
k
No	m
ax
Treatm
ent	m
ax	dose:	
N/R
Baseline:	M
orphine	
M
ean	202	M
M
E
M
ethadone	
W
k	2	m
ean:	513	M
M
E
M
th	3	m
ean:	564	
M
M
E
M
th	9	m
ean:	568	
M
M
E
Total:	5/12	patients	(41.6%
)	sw
itched	
back	to	m
orphine
Reasons	for	discontinuation	at	3-day	
opioid	sw
itching,	1-w
k	titration,	and	4-w
k	
consultation:
	Insufficient	pain	control	(1,-,-)
Insufficient	pain	control	&
	anxiety	(1,-,-)
Sedation	(-,	1,-)
Drow
siness	(-,	1,-)
Profuse	sw
eating	(-,-,	1)
Total:	N/S
Sleep-related	AE/SAE:
1-w
k	titration
Sedation		(1)
Single-item
	sleep	difficulties	scale	(self	report)
M
ean	values	indicated	a	slight	decrease	in	sleep	
difficulties	(*Outcom
e	data	not	provided)	
4	patients	reported	a	clinically	significant	decrease	of	
sleep	difficulties,	and	5	patients	reported	a	decrease	of	
fatigue,	at	9-m
th	com
pared	to	baseline
Brief	Pain	Inventory	0-10	NRS	score	(self	report)
The	average	decrease	in	m
ean	pain	intensity	w
as	4	at	
baseline	and	2.9	at	9-m
th	(n=6)	follow
-ups
EORTC	Q
LQ
-C30	pain	sym
ptom
	scale	(self	report)
M
ean	reductions	in	pain	sym
ptom
	scale	w
ere	24,	29	and	
38	at	2-w
k,	3-m
th,	and	9-m
th
com
pared	to	baseline.	A	change	of	>10	on	the	0-100	scale	
w
as	considered	clinically	significant
High
Authors,	yr	
[ref.];country
O
pioids	regim
en
Daily	dose	in	M
M
E
Attrition
Reason/tim
ing	(n)
Adverse	events/Serious	
adverse	events
Sleep-related	AE/SAE		(n)
Sleep	outcom
es
Pain	outcom
es
Risk	of	
bias^
Gajria	et	al.,	2008	
[38];	USA
Hydrom
orphone	
(OROS;	Osm
otic	CR	
oral	delivery	system
)
Start	dose:	8	m
g/day
Increases	by	8m
g	
M
ax:	64	m
g/day	
vs.
O
xycodone	
(tw
ice-daily	ER)
Start	dose:	20	m
g/day
Increases	by	10-40	
m
g/day
M
ax:160	m
g/day
Treatm
ent	m
ean	
dose:	N/R
Hydrom
orphone	
Start	dose:	32	M
M
E	
Increases	by	32	M
M
E
M
ax	256	M
M
E	
O
xycodone	
Start	dose:	30	M
M
E	
Increases	by	15-60	
M
M
E
M
ax	240	M
M
E
Total:	57	/140	patients	(40.7%
)	at	
random
isation	#
Reasons	for	discontinutation	after	
random
isation	and	during	treatm
ent	
(OROS:ER)
	Protocol	violation	(1,	-:-)
Lost	to	follow
-up	(1,	-:-)
Lack	of	efficacy	(-,	1:3)
Adverse	events	(-,	25:22)
Consent	w
ithdraw
n	(-,	1:2)
Adm
inistrative	reasons	(-,	1:0)
*	Further	exclusion	took	place	due	to	one	
trial	site	receiving	a	NIDPOE,	resulting	in	
74	patients	com
pleted	the	study
Total:	4	records	of	SAE	and	169	
records	of	AE	for	the	138	w
ho	
received	OROS:	ER	#
Sleep-related	AE/SAE:
Som
nolence	(18	:	12)
M
OS	Sleep	Scale	(self	report)
OROS	show
ed	significant	but	sm
all	im
provem
ents	on		
sleep	quantity,	snoring,	aw
akening	short	of	breath,	
m
oderate	im
provem
ents	on	adequacy,	disturbance,	and	
both	sleep	problem
	indices,	com
pared	to	baseline.	
ERs	show
ed	significant	but	sm
all	im
provem
ents	on	sleep	
quantity	and	sleep	index	II	and	m
oderate	im
provem
ent	
on	sleep	disturbance,	com
pared	to	baseline.	
Of	the	7	subscales,	differences	w
ere	observed	in	favour	of	
OROS	on	aw
akening	short	of	breath	or	w
ith	a	headache	
and	sleep	index	I
OA	sym
ptom
s	&
	disability	(W
OM
AC)	(self	report)
Both	treatm
ents	show
ed	large	reductions	in	pain,	
stiffness,	physical	function	and	the	global	score,	
com
pared	to	baseline.	
M
ean	values	(SD)	for	the	W
OM
AC	pain	subscale	at	
baseline	and	end	of	study	w
ere:
OROS:	6.27	(1.61),	4.11	(1.99)
ER:	6.06	(1.5),	4.08	(2.0)
Daily	pain	relief	scale	(self	report)
At	the	end	of	study	and	across	groups	(n=116	data	
available),	42	(36.2%
)	reported	com
plete	relief,	54	
(46.6%
)	m
oderate	relief,	13	(11.2%
)	slight	relief,	and	7	
(6%
)	no	relief.	Patients	w
ith	greater	pain	relief	show
ed	
greater	im
provem
ent	on	the	M
OS	sleep	scale	and	
W
OM
AC	m
easures.	
High
Jam
ison	et	al.,	1998	
[33];	USA
Titration	phase:
(Titrated-dose	
O
xycodone,	IR	+		
m
orphine	sulphate,	
SuR)	
M
ax	total:	200M
M
E
Study	treatm
ent:	
Set-dose	oxycodone,		
IRMax	20	m
g/day
vs.	
Titrated-dose	
O
xycodone,	IR	+	
m
orphine	sulphate,	
SuR	
M
ax	200	M
M
E	total
vs.	
Naproxen	
M
ax	1000	m
g/day
Titration	phase:
M
ean:	62	M
M
E
M
ax:	200	M
M
E
Study	treatm
ent:	
Set-dose	oxycodone
M
ax:	30	M
M
E
Titrated-dose	
oxycodone:		
M
ean:	41	M
M
E;	M
ax:	
130	M
M
E
*	M
eans	and	m
ax	
w
ere	provided	in	
M
M
E.	The	conversion	
factor	is	not	reported
Total:	1/36	patients	(0.03%
)	dropped	out	
at	M
th	7	(during	the	titration	phase)
*	In	addition,	3	patients	(1in	titrated-dose	
and	2	in	set-dose)	discontinued	after	M
th	
1	due	to	intolerance	to	the	drug.	Another	
3	patients	discontinued	as	they	could	not	
tolerate	the	adverse	effects	of	opioid	
during	the	titration	phase.	
Total:	N/R
Sleep-related	AE/SAE:
%
	reported	during	the	
Experim
ental	Phase	by	group	
(No	opioid	:	Set	dose	:	Titrated	
dose)	are:
Drow
siness	(14.6	:	22.1	:	36.9)
Nightm
ares	(1.0	:	1.0	:	1.7)
Hours	of	sleep	(self	report)
No	differences	in	hrs	of	sleep	w
ere	found	betw
een	groups	
during	the	Experim
ental	Phase.	The	m
ean	(SD)	no.	of	hrs	
of	sleep	by	group	(No	opioid	:	Set	dose	:	Titrated	dose)	
w
ere	6.1	(2.69)	5.9	(2.05)	and	5.9	(2.31).
No	differences	in	hrs	of	sleep	w
ere	found	for	changes	in	
opioid	dose.	The	m
ean	no.	of	hrs	of	sleep	by	changes	in	
dose		(reduction	of	>75	m
g	:	reduction	of	5-75	m
g	:		no	
change	:	increase	of	5-110	m
g	:	increase	of	>110	m
g)	
w
ere:	6.2,	5.8,	6.0,	6.3,	and	5.8.
Pain	ratings	(average,	current,	highest,	low
est;	0-100;	
0=none,	100=w
orst	possible	pain)	(self	report)
M
ean	scores	for	pain	ratings	decreased	in	all	groups	
during	the	Experim
ental	Phase.	M
ean	(SD)	pain	rating	(0-
100)	w
as	65.5	(19.05)	for	the	No	Opioid	group	(n=12),	
59.8	(16.65)	Set	Dose	group	(n=13)	and	54.9	(15.87)	for	
the	Titrated	Dose	group	(n=11).	The	titrated-dose	group	
had	less	pain	than	the	other	tw
o	groups.	Both	opioid	
groups	also	w
ere	found	to	have	significantly	less	pain	
than	the	naproxen-only	group.
A	curvilinear	relation	w
as	found	betw
een	w
eekly	dose	
change	and	pain	ratings.	Patients	w
ho	either	increased	or	
decreased	their	dose	reported	less	pain	than	those	w
ho	
did	not	change	their	dose.	The	m
ean	average	pain	rating	
by	changes	in	dose		(reduction	of	>75m
g	:	reduction	of	5-
75m
g	:		no	change	:	increase	of	5-110m
g	:	increase	of	
>110m
g)	w
ere:	54.6,	58.8,	63.6,	55.8,	and	55.9.
High
Karlsson	&
	
Berggren,	2009	[39];	
Sw
eden
Transderm
al	
buprenorphine	
Patch	dosage:	5,	10,	
or	20	ug/h	
M
ax	:	20	ug/h
vs.
Tram
adol,	ER
Pill	dosage:	75,	100,	
150,	or	200	m
g	
M
ax	:400	m
g/day
RM
:	Paracetam
ol	
(<2000	m
g/day)
Treatm
ent	start	and		
m
ean	dose:	N/R
Buprenorphine:	
M
ax	dose:	40	M
M
E	
Tram
adol:	
M
ax	dose:	40	M
M
E
Total:	35/135	patients	(25.9%
),	14	in	the		
buprenorphine	group.	21	in	the	tram
adol	
group
Reasons	for	discontinuation	betw
een	
random
isation	and	end	of	strudy	
(Buprenorphine:Tram
adol):
Adverse	event	(10	:	19)
Protocol	violations	(3	:	0)
W
ithdraw
al	of	consent	(0	:	1)
Lost	to	follow
-up	(0	:	1)
Other	(1	:	0)
Total:	226	AEs	reported	in	61	
patients	(88.4%
)	in	
buprenorphine	group	and	152	
AEs	reported	in	51	patients	
(78.5%
)	in	the	tram
adol	group.	
Tim
ing	of	AEs	unspecified.
Sleep-related	AE/SAE	
(Buprenorphine:	Tram
adol):
Fatigue	(10	:	12)
Sleep	disturbance	frequency	(self	report)
Decreased	by	2	nights	from
	baseline	to	study	com
pletion	
in	both	treatm
ent	groups	(Buprenorphine=2.5	nights	:	
Tram
adol=2.9	nights).		Groups	did	not	differ	significantly
Q
uality	of	sleep	categorical	rating	(self	report)
Im
proved	by	at	least	1	sleep	quality	category	from
	
baseline	to	study	com
pletion	in	both	treatm
ent	groups	
(Buprenorphine=59%
	:	Tram
adol=48%
).	Groups	did	not	
differ	significantly
Pain	intensity	change	(BS-11)	(self	report)
Decreased	m
ean	BS-11	pain	score	from
	baseline	to	study	(-
2.26	:	-2.09).	Groups	did	not	differ	significantly		
OA	sym
ptom
s	&
	disability	(W
OM
AC)		(self	report)
Both	groups	show
ed	im
provem
ent	on	all	scales.	Groups	
did	not	differ	significantly
High
Authors,	yr	
[ref.];country
O
pioids	regim
en
Daily	dose	in	M
M
E
Attrition
Reason/tim
ing	(n)
Adverse	events/Serious	
adverse	events
Sleep-related	AE/SAE		(n)
Sleep	outcom
es
Pain	outcom
es
Risk	of	
bias^
Langford	et	al.,	2006	
[40];	Canada,	Czech	
Republic,	Hungary,	
Poland,	Slovakia,	&
	
UK
Transderm
al	fentanyl
dosing	per	72h
Start	dose:	25	μg/h		
increases:	1	extra	
patch	every	3	days
M
edian:	1.7	patches=	
42.5	μg/h
M
ax:	100	μg/h	
vs.
Placebo	
(patch	of	sam
e	
aspect,	m
edian	use	=	
2.4	patches)
RM
:	Paracetam
ol	up	
to	4	gr/day
Start	dose:	60	M
M
E	
M
edian	dose:	102	
M
M
E
M
ax	dose:	240	M
M
E
Total:	200/399	(50.1%
);	96	in	the	
Transderm
al	fentanyl	group,	104	in	the	
Placebo	group
Reasons	for	discontinuation	throughout	
study	(Transderm
al	fentanyl	:	Placebo):
Adverse	event	(54	:	20)
Insufficient	efficacy	(15	:	64)
W
ithdrew
	consent	(17	:	13)
Lost	to	follow
-up	(1	:	0)
Other	(9	:	7)
Total:	169	patients	(78%
)	in	the	
Transderm
al	fentanyl	group	
and	101	patients	(51%
)	in	the	
placebo	group	reported	>1	AE		
during	the	treatm
ent	phase;	51	
(28%
)	and	25	(13%
)		during	the	
tapering-off	phase.
Sleep-related	AE/SAE:	
During	the	treatm
ent	phase	
(Transderm
al	fentanyl	:	
Placebo)	
Som
nolence	(48	:	7)
During	the	tapering-off	phase	
(Transderm
al	fentanyl	:	
Placebo)
Insom
nia	(16	:	8)
%
	reporting	m
ild-m
oderate	problem
s	sleeping		(self	
report)
Sim
ilar	proportions	in	each	group	also	reported	m
ild	or	
m
oderate	problem
s	w
ith	sleeping	(Transderm
al	
fentanyl=36%
	:	Placebo	Group:	37%
)
%
	reporting	severe	insom
nia	(self	report)
A	higher	proportion	of	patients	receiving	Transderm
al	
fentanyl	group	reported	severe	insom
nia	(Transderm
al	
fentanyl=22%
	:	Placebo	Group:	8%
)	
Change	in	Pain	VAS	from
	baseline	(expressed	w
ith	area	
under	the	curve)	(self	report)
Treatm
ent	w
ith	transderm
al	fentanyl	w
as	associated	w
ith	
significantly	better	pain	relief	than	that	w
ith	the	placebo	
patch;	the	prim
ary	end	point	of	the	AUCM
Bavg	w
as		
20±1.4	(m
ean	+	SEM
)	for	patients	receiving	transderm
al	
fentanyl	and		14.6±1.4	for	patients	receiving	placebo	(P=	
0.007)
OA	sym
ptom
s	&
	disability	(W
OM
AC)	(self	report)
W
OM
AC	scores	for	pain,	stiffness,	and	physical	function	
im
proved	significantly	from
	baseline	to	study	end	in	both	
groups.	How
ever,	the	overall	W
OM
AC	score	and	the	pain	
score	w
ere	significantly	better	in	the	transderm
al	fentanyl	
group.	Stiffness	and	physical	functioning	scores	show
ed	
nonsignificant	trends	in	favour	of	the	transderm
al	
fentanyl	group
High
M
a	et	al.,	2008	[41];	
China
O
xycodone,	CR	(Oxy-
CR;	per	12h)
Start	dose:	5-10	m
g	
25-50%
	increase	or	
decrease	at	day	3
No	m
ax	described
Treatm
ent	m
ean	and	
m
ax	dose:	N/R
Start	dose:	15-30	
M
M
E
Total:	104/166	patients	(89.7%
)	
throughout	the	w
hole	study
Reasons	for	discontinutation	at	Day	7	
(Oxy-CR	:	Placebo)
Itching	(1	:	0	)
Nausea	(0	:	1)
*No	further	details	given	on	attrition	
Total:	120	records	of	AE			
Sleep-related	AE/SAE:	
Day	7	(Oxy-CR	:	Placebo)
Som
nolence	(6	:	0)
Day	14	(Oxy-CR	:	Placebo)
Som
nolence	(1	:	0)
Q
uality	of	sleep	categorical	rating	(self	report)
Oxy-CR	group	had	significantly	better	outcom
e	for	sleep	
quality	rating	com
pared	to	placebo,	from
	day	7	onw
ards
At	the	end	of	study,	the	no.	of	people	reporting	good,	
average	&
	bad	sleep	quality	w
ere:
Oxy-CR:	5	(71.4%
),	2	(28.6%
),	0	(0%
)
Placebo:	0	(0%
),	3	(60%
),	2(40%
)
Pain	intensity	(0-10	VAS;	VAS	anchors	N/S)	(self	report)
Oxy-CR	group	had	significantly	low
er	pain	scores,	
com
pared	to	placebo,	from
	day	7		onw
ards.	The	decrease	
plateaued	at	day	21	w
ith	63%
	decrease	from
	the	baseline
Unclear
M
itra	et	al.,	2013	
[43];	Australia
Transderm
al	
buprenorphine
start	dose:	12.5	μg/h
vs.
Transderm
al	fentanyl	
start	dose:	at	5μg/h
Increase	in	both	arm
s	
to	optim
al	dose	over	
4	w
ks	
RM
:	Paracetam
ol	or	
low
-dose	NSAIDs	
(dosage	N/S)
Treatm
ent	m
ean	and	
m
ax	dose:	N/R
Start	dose:	
Fentanyl:	12	M
M
E
Buprenorphine:	25	
M
M
E
Total:	30/46	patients	(65.2%
)	
Side	effects	or	reporting	unsatisfactory	
pain	(TDB:	8/22		:	TDF:	8/24)
Total:	N/S
Sleep-related	AE/SAE:	
"Im
m
ediate	side	effects,	
nam
ely	nightm
ares,	nausea	
and	increased	drow
siness,	
w
ere	show
n	to	be	m
ore	
intense	w
ith	TDF	patch…
TDB	
had	a	stronger	delayed	onset	
of	adverse	effects…
M
ore	TDB	
users	com
plained	of	local	skin	
reactions,	such	as	itching,	
redness,	sw
elling,	blisters,	etc,	
..."
Q
uality	of	sleep	rating	(0=Very	good,1=	good,	2=fair,	or	
3=poor)	from
	the	SPAASM
S	score	card	(self	report)
There	w
ere	no	significant	differences	betw
een	the	tw
o	
groups	in	SPAASM
S	scores.	(*Outcom
e	data	not	
provided).	
Im
provem
ent	in	sleep	quality	for	the	initial	6	m
ths	by	
both	groups	w
ere	not	statistically	significant.	After	6	
m
ths,	sleep	quality	stabilised	in	both	groups.	
Pain	intensity	NRS	(0-10;	0	=no	pain,	10=m
ost	pain)	(self	
report)
No	significant	difference	betw
een	groups	and	over	tim
e.
High
Authors,	yr	
[ref.];country
O
pioids	regim
en
Daily	dose	in	M
M
E
Attrition
Reason/tim
ing	(n)
Adverse	events/Serious	
adverse	events
Sleep-related	AE/SAE		(n)
Sleep	outcom
es
Pain	outcom
es
Risk	of	
bias^
Peloso	et	al.,	2000	
[48];	Canada
Codeine,	CR	
(CR-C)	
start	dose:50	m
g/12h
W
eekly	increases	
M
ean:	159	m
g/12h
M
ax:	200	m
g/12h	
vs.	
Placebo	(identical	
looking	pills)
RM
:	Acetam
inophen	
650	m
g	m
ax	3x/day
Start	dose:	7.5	M
M
E
M
ean	dose:	24	M
M
E
M
ax	dose:	30	M
M
E
Total:		37/103	patients	(35.9%
);	20	in	the	
controlled-release	codeine	group	and	17	
in	the	placebo	group
Adverse	event	(15	:	4)
Unrelated	illness	(1	:	0)
Inadequate	pain	control	(1	:	5)
Patient	noncom
pliant	(1	:	1)
Patient	w
ithdraw
al	(1	:	1)
Protocol	violation	(0	:	1)
Other	reasons	(1	:	5)	
Total:	N/S
Sleep-related	AE/SAE:	
"For	all	patients	random
ized	to	
treatm
ent,	a	significantly	larger	
proportion	(p	<	0.01)	of	
controlled	release	codeine	
patients	experienced	the	
follow
ing	side	effects	than	the	
placebo	group:	constipation	
(49%
,	11%
),	som
nolence	(39%
,	
10%
),	dizziness	(33%
,	8%
),	and	
overall	(82%
,	58%
)."
15.7%
	of	all	random
ised	
controlled	release	codeine	
patients	(n=51)	experienced	
som
nolence	
M
ulti-item
	sleep	assessm
ent	(self	report)
3	of	the	7	item
s	w
ere	reported.	These	show
ed	superiority	
of	controlled-release	codeine	over	placebo,	w
ith	less	
need	for	m
edication	(im
provem
ents	of	73.3%
	and	10.4%
,	
p	=	0.004),	less	pain	on	aw
akening	(im
provem
ents	of	
76.4%
	and	22.8%
,	p	=	0.02),	and	less	trouble	falling	asleep	
(im
provem
ents	of	72.5%
	and	37.7%
,	p	=	0.02).	
No	inform
ation	on	the	rem
aining	4	sleep	item
s.	
No	Com
posite	Sleep	Score	w
as	calculated	or	reported
W
OM
AC	pain	VAS	(0-500m
m
)	(self	report)
There	w
as	an	im
provem
ent	in	pain	of	44.8%
	in	the	
controlled-release	codeine	group,	com
pared	w
ith	12.3%
	
taking	placebo(p	=0.0004)	
W
eekly	pain	intensity	VAS	(0-100m
m
)	(self	report)
Sim
ilar	significant	im
provem
ents	w
ere	also	found	for	
w
eekly	pain	VAS	score	(p	=	0.0001)
There	w
as	a	significant	w
eek	by	drug	interaction	for	both	
W
OM
AC	pain	VAS	(p	=	0.02)and	the	w
eekly	pain	score	(p	
=0.001),	suggesting	an	im
provem
ent	in	pain	over	the	4	
w
ks	of	the	study	w
ith	controlled-release	codeine	and	a	
lack	of	change	over	tim
e	w
ith	placebo.
Unclear
Raja	et	al.,	2002	
[42];	USA
M
orphine,	CR
start	dose:		15	m
g	
Tw
ice	w
eekly	increase
M
ean:	91	m
g
M
ax:	240	m
g
(alternative:	
M
ethadone:	
start	dose:	5	m
g,	
M
ean:	15	m
g)
vs.
Nortriptyline	(m
ean	
89	m
g)	(alternative:	
desipram
ine	m
ean	63	
m
g	)
vs.	
Placebo
RM
:	Acetam
inophen	
and	NSAIDs
M
orphine:
Start	dose:	15	M
M
E
M
ean:	91	M
M
E
M
ax:	240	M
M
E
M
ethadone:	
Start	dose:	20	M
M
E
M
ean:	60	M
M
E
M
ax	N/R
Total:	32/76	random
ised	(42.1%
),	5	after	
random
isation,	11	after	treatm
ent	period	
1,	10	after	treatm
ent	period	2,	6	after	
treatm
ent	period	3.
Prim
ary	reasons	for	drop-out	(opioid	:	
tricyclic	antidepressant)
Side	effect	(7	:	2)
Other	m
edical	problem
s	(6	:	1)
Concerns	of	fam
ily	m
em
bers	(5	:	2)	
M
arked	pain	reduction	&
	w
ish	to	use	
other	drugs	(2	:	1)
Total:	387	AEs;	234	in	the	
Opioid	group,	97	in	the	TCA	
group,	56	in	the	Placebo	group
Sleep-related	AE/SAE:	
Throughout	treatm
ent	and	
m
aintenance	phase	(Opioid	:	
TCA	:	Placebo)
Drow
siness	(48	:	18	:	14)
Single	rating	on	sleep	interference	(0-6)	(self	report)
Com
parable	reductions	in	sleep	disturbance	w
ere	
observed	w
ith	opioids	(Baseline=2.7±2.1,	M
aintenance	
=2.5±1.7;	p	=	0.01)	and	TCA	(Baseline	=3.2±2.0,	
M
aintenance	=2.5±1.9;	p	=	0.02),	w
hereas	placebo	
(Baseline	=	3.2±1.8,	M
aintenance	=	2.9±1.9)	had	no	effect	
on	sleep	ratings.
Pain	intensity	rating	(0-10)	(self	report)
Greater	m
ean	decreases	in	pain	ratings
follow
ed	therapy	w
ith	both	TCA	(m
ean	reduction	of	1.4;	
95%
	CI=1.8	to	0.9,	n=59)	and	opioids	(reduction	of	1.9;	
95%
	CI=	2.3	to	1.4,	n=64)	than	w
ith	placebo	(reduction	of	
0.2;	95%
	CI	0.7	to	0.2,	n=56,	p<0.001),	w
hich	had	no	
effect	on	pain.
Pain	relief	rating	(0-100%
)	(self	report)
The	m
ean	percentage	pain	relief	ratings	during	treatm
ent	
w
ith	opioids	(38%
;	95%
	CI
30	to	46,	p<0.001)	and	TCA	(32%
;	95%
	CI=24	to	40,	
p<0.001)	w
ere	greater	than	during	the	placebo	phase	
(11%
;	95%
	CI=6	to	16).	The	tw
o	active	drug	treatm
ents	
w
ere	not	significantly	different.
				
High
Authors,	yr	
[ref.];country
O
pioids	regim
en
Daily	dose	in	M
M
E
Attrition
Reason/tim
ing	(n)
Adverse	events/Serious	
adverse	events
Sleep-related	AE/SAE		(n)
Sleep	outcom
es
Pain	outcom
es
Risk	of	
bias^
Rauck	et	al.,	2006	
[43];	USA
M
orphine	sulphate,	
ER	
(A-M
Q
D;	once-a-day	
capsules	taken	in	the	
m
orning)	
m
ean:	69.9	m
g
vs.
O
xycodone	
hydrochloride,	ER	
(O-ER;	tw
ice-a-day	
controlled-release	
tablets)
m
ean:	60.7	m
g
RM
:	Ibuprofen	(<2400	
m
g/day)
Treatm
ent	start	and	
m
ax	dose:	N/R
M
ean	dose	(intention	
to	treat):
A-M
Q
D:	70	M
M
E
O
-ER:	91	M
M
E
Total:	172/392	patients	(43.8%
);	93/203	
(45.8%
)	in	A-M
Q
D	and	79/189	(41.8%
)	in	
O-ER
During	titration:	
126/172	(73.3%
)	across	groups
During	evaluation:
46/172	(26.7%
)	across	groups
Reasons	for	attrition	not	specified	by	
tim
ing	of	the	study,	but	by	group	(A-M
DQ
	
:	O-ER):	
Adverse	event	(38	:	27)
W
ithdraw
al	of	consent	(18	:	19)
Lost	to	follow
-up	(12	:	7)
Lack	of	efficacy	(10	:	6)
Noncom
pliance	(6	:	5)
Opioid	dose	not	stabilised	(5	:	4)
Investigator	w
ithdraw
al	of	patient	(1	:	5)
Protocol	violation	(1	:	4)
Other	(2	:	2)	
Total:	16	SAEs,	but	tim
ing	and	
nature	not	specified.	The	
incidence	and	severity	of	AEs	
w
ere	com
parable	betw
een	
groups
Sleep-related	AE/SAE:		
Drow
siness
PSQ
I	(self	report)
Both	treatm
ents	resulted	in	im
proved	PSQ
I	scores,	w
ith	
im
provem
ent	noted	by	the	end	of	titration	and	
continuing	during	the	8-w
k	evaluation	phase.	
The	relative	changes	in	PSQ
I	scores	from
	study	w
as	
significantly	better	in	the	A-M
Q
D	than	the	O-ER	group	at	
w
k	4	(30%
	vs	17%
	im
provem
ent,	p	=	0.024),	w
k8	(33%
	vs.	
17%
,	p	=	0.006)	and	w
ks	1,	4,	&
	8	com
bined	(30%
	vs.	16%
,	
p	=	0.013).	
Pain	intensity	(Brief	Pain	Inventory)	(self	report)
Both	groups	show
ed	a	reduction	in	pain	scores	from
	the	
baseline	to	evaluation	phase.	
The	w
eekly	average	of	BPI	pain	scores	rem
ained	<4	in	
both	groups,	w
ith	A-M
Q
D's	pain	score	being	low
er	than	O-
ER's	at	each	tim
e	point	and	the	difference	reaching	
statistical	significance	at	w
ks	2	&
	7.		
High
Rauck	et	al.,	2016	
[44];	USA
Buprenorphine,	
buccal	(BBUP)
Start	dose:	75μg	
once/day	
then	increase	to	75μg	
tw
ice/day,	and	then	
either	150,	300	or	450	
μg	tw
ice/day
RM
:	
2	first	w
ks:
Hydrocodone/Acetam
inophen	(<	10	m
g/650	
m
g/day)
thereafter:		
Acetam
inophen	
(<1000	m
g/day)
Treatm
ent	m
ean	and	
m
ax	dose:	N/R
Average	dose	at	tim
e	
of	random
isation:		26	
M
M
E
Total:	402/752	(53.5%
)
Reasons	for	discontinuation	during	pre-
titration,	titration,	and	treatm
ent	
(BBUP:Placebo):
	Not	dosed	(3,-,-)
Adverse	event	(-,	109,	13:7)
Lack	of	efficacy	(-,	33,	8:23)
Protocol	violation	(-,	24,	7:10)
Opioid	w
ithdraw
al	(-,-,	3:1)
W
ithdraw
al	by	subject	(-,	34,	12:8)
Lost	to	follow
-up	(-,	22,	4:9)
Other	(-,	68,	7:0)
Total:	540/749	patients	
(72.1%
)	reported	>1	AE	and	4	
(0.5%
)	reported	>1	SAE	during	
titration.	During	treatm
ent,	
94/229	patients	(41%
)		in	the	
BBUP	group	and	101/232	
(43.5%
)	in	the	Placebo	group	
reported	>1	AE;	3	(1.3%
)	in	the	
BBUP	and	1	(0.4%
)	in	the	
Placebo	group	reported	>1	
SAE.	
Sleep-related	AE/SAE:	
Titration	
Som
nolence	(52)
Fatigue	(37)
Treatm
ent	(BBUP	:	Placebo)
Som
nolence	(2	:	1)
Fatigue	(0	:	2)
M
OS	Sleep	Scale	(self	report)
"..no	significant	differences	betw
een	groups	on	the	
change	from
	baseline…
"
*Outcom
e	data	not	provided
Pain	intensity	(0-10	NRS)	(self	report)
Pain	control	w
as	superior	w
ith	BBUP	than	placebo.	M
ean	
pain	intensity	increase	at	w
eek	12	from
	baseline	w
as	
significantly	greater	in	patients	treated	w
ith	placebo	
(1.59±2.04)	than	BBUP		(0.94±1.85),	p=0.001).
The	BBUP	group	had	a	significantly	higher	proportion	of	
patients	w
ho	achieved	a	>30%
	reduction	in	pain	(63%
	:	
47%
,	p	=0.001)	than	the	placebo	group,	but	not	for	
achieving	>50%
	reduction	in	pain	(41%
	:	33%
)
Disability	(Roland	M
orris	Disability	Q
uestionnaire)	(self	
report)
decreased	30%
	after	titration	w
ith	BBUP,	but	scores	of	
the	BBUP	group	did	not	differ	from
	the	placebo	group	
after	treatm
ent	
High
Authors,	yr	
[ref.];country
O
pioids	regim
en
Daily	dose	in	M
M
E
Attrition
Reason/tim
ing	(n)
Adverse	events/Serious	
adverse	events
Sleep-related	AE/SAE		(n)
Sleep	outcom
es
Pain	outcom
es
Risk	of	
bias^
Rosenthal	et	al.,	
2007	[49];	USA
M
orphine	sulphate,	
ER	(A-M
Q
D,	once	a	
day)
Start	dose:30	m
g/day	
Increase	at	day	6	if	
needed
M
ax:	60	m
g/day
Start	dose:	30	M
M
E
After	day	6	
N=	10	on	30	M
M
E	
N=	21	on	60	M
M
E
Total:	3/34	patients	(8.8%
)	did	not	
com
plete	treatm
ent	long	enough	to	be	
considered	evaluable	
Reasons	of	attrition:	N/S
Total:	22	(71%
)	patients	had	>1	
AE,	1	(3.2%
)	patient	had	a	SAE.
Sleep-related	AE/SAE:	
Treatm
ent:
Sedation	(5)
Severe	sedation	&
	
unresponsiveness	(1)
PSG	(Objective)
A-M
Q
D	increased	sleep	efficiency	[76.5%
	(previous	
analgesics)	->	81.8%
	(placebo)	->	83.8%
	(A-M
Q
D)]	and	
total	sleep	tim
e	[367	m
in	(previous	analgesics)	->391.1	
m
in	(placebo)	->	402.5	m
in	(A-M
Q
D)]	vs.	previous	
analgesics,	but	not	vs.	placebo.	A-M
Q
D	reduced	REM
	
latency	[113.9	m
in	(previous	analgesic)	->	84.1	m
in	
(placebo)	->	68.5	m
in	(A-M
Q
D)]	vs.	both	previous	
analgesics	and	placebo
Sleep	quality	(0=poor,	100=best	sleep)	(self	report)
A-M
Q
D	increased	overall	sleep	quality	rating	(64.3)	vs.	
previous	analgesics	(33.3)	and	baseline	placebo-run-in	
(40.9)
Sleep	duration	(hrs	of	sleep	reported)	(self	report)
A-M
Q
D	increased	overall	sleep	duration	(6.6)	vs.	previous	
analgesics	(5.9)	and	baseline	placebo-run-in	(6.1)
ESS	(self	report)
A-M
Q
D	increased	sleepiness	(6.6)	vs.	baseline	placebo-
run-in	(4.7),	but	not	vs.	previous	analgesics	(5.3)
Pain	intensity	(BPI	avg	pain	score:	NRS	0=no	pain,	
10=w
orst	pain)	(self	report)
Reduced	w
ith	A-M
Q
D	(4.1),	com
pared	w
ith	previous	
analgesics	(6.1)	and	placebo	(6.1)
Pain	relief	im
pression	(rating	0=none,	5=excellent)	(self	
report)
Higher	w
ith	A-M
Q
D	(3.5),	com
pared	w
ith	previous	
analgesic	(2.4)	and	placebo	(2.0)
High
Sim
pson	et	al.,	1997	
[50];	USA
Transderm
al	fentanyl	
5,	50,	75,	or	100	μg/h
RM
:	Short	acting	oral	
opioids	(type	&
	
dosage	N/S)
Treatm
ent	start	and	
m
ax	dose:	N/R
M
ean	dose:	78		M
M
E
Total:	18/68	patients	(26.5%
)
Titration
Nausea/vom
iting	(10)
Drow
siness	(1)
Protocol	violation	(3)
Transport	issues	(4)
Total:	85	records	of	AE
Sleep-related	AE/SAE:	
Titration	&
	m
aintenance:
Sleepiness	(7)
VHS	(self	report)
No	significant	change	in	quality	of	sleep	based	on	the	
sum
m
ed	analog	VSH	scale,	although	there	w
as	a	
significant	im
provem
ent	in	the	subscale	of	num
ber	of	
aw
akenings,	from
	77.1	±22.3	m
in	to	66.24	±28.16	m
in	
(p<0.014).	No	other	subscales	show
ed	significant	
im
provem
ent.	
Pain	intensity	(VAS)	(self	report)
Declined	significantly	from
	before	(79.8±30.3)	to	after	
(44.2±26.68)
Pain	relief	(num
erical	pain	relief	score)	(self	report)
Declined	significantly	from
	before	(8.02±1.34)	to	after	
(6.02±2.61)	(p<0.0001)
Pain	disability	(Osw
estry	Disability	Q
uestionnaire)	(self	
report)
Decreased	significantly	from
	before	(38.4+6.29)	to	after	
(35.86±8.55)	(p	<0.016)
Pain	disability	(Pain	Disability	Index)		(self	report)
Decreased	significantly	from
	before	(49.86±10.91)	to	after	
(44.7±14.27)	(p	<0.007)
High
Thorne	et	al.,	2008	
[35];	Canada
Tram
adol,	CR	
Start	dose	150	m
g	
w
eekly	titration	
M
ean:	340	m
g		
M
ax.	400	m
g/day
vs.
Placebo
RM
:	Acetam
inophen,	
m
ax.	650	m
g	up	to	6	
x/day
Start	dose:	15	M
M
E
M
ean	dose:	34	M
M
E
M
ax	dose:	40	M
M
E
Total:	25/100	patients	(25%
)
By	treatm
ent	phase	(CR	Tram
adol	:	
Placebo)
Adverse	event	(12	:	3)
Lack	of	efficacy	(1	:	3)	
Consent	w
ithdraw
n	(1	:	2)
Lost	to	follow
-up	(1	:	0)
Protocol	violation	(0	:	1)	
Other	(1	:	0)
Total:		288	during	the	CR	
Tram
adol	phase	and	166	
during	the	Placebo	phase
Sleep-related	AE/SAE:	
By	treatm
ent	phase	(CR	
Tram
adol	:	Placebo)	are:	
Som
nolence	(35	:	19)
Insom
nia	(0	:	4)
		
M
ulti-item
	sleep	assessm
ent	(self	report)
Significant	betw
een-treatm
ent	and	treatm
ent-baseline	
differences	in	the	Com
posite	Sleep	Score	(Baseline:	
183.4±123.6,	CR	Tram
adol:	104.7±98,	Placebo:	
141±108.2)	(p	=	0.0008)
Significantly	better	scores	for	the	CR	tram
adol	group,	
com
pared	w
ith	the	placebo	group	and	w
ith	baseline,	in	
five	of	eight	item
s	on	the	questionnaire	(‘trouble	falling	
asleep’,	‘needed	pain	m
edication	to	sleep’,	‘needed	sleep	
m
edication	to	sleep’,	‘aw
akened	by	pain	in	the	m
orning’,	
‘average	hours	of	sleep	per	night’).	
No	significant	im
provem
ents	w
ere	observed	for	the	
"aw
akened	by	pain	at	night',	'partner	aw
akened',	and	
'quality	of	sleep'	item
s.
Pain	intensity	(VAS)	(self	report)
During	the	last	w
eek	of	treatm
ent,	the	m
ean	VAS	score	
w
as	significantly	low
er	in	the	CR	tram
adol	group	(37.4	
±23.9	m
m
)	than	in	the	placebo	group	(45.1	±24.3	m
m
;	
P=0.0009).
OA	sym
ptom
s	&
	disability	(W
OM
AC)		(self	report)
The	com
posite	scores	for	the	pain	
inventory	of	the	W
OM
AC	OA	index	during	the	last	w
eek	
of	each	treatm
ent	phase	w
ere	significantly	better	
follow
ing	CR	tram
adol	treatm
ent,	com
pared	w
ith	placebo	
treatm
ent.	The	com
posite	scores	for	the	pain	inventory	
w
ere	189.0	±105.0	m
m
	(34.5%
	Change	From
	Baseline,	
P=0.0001)	for	CR	tram
adol	treatm
ent	and	230.0	±115.4	
m
m
	(19.8%
	CFB,	P=0.0001)	for
placebo	treatm
ent	(P=0.0007).
Unclear
Authors,	yr	
[ref.];country
O
pioids	regim
en
Daily	dose	in	M
M
E
Attrition
Reason/tim
ing	(n)
Adverse	events/Serious	
adverse	events
Sleep-related	AE/SAE		(n)
Sleep	outcom
es
Pain	outcom
es
Risk	of	
bias^
Vorsanger	et	al.,	
2008	[36];	USA	
Tram
adol,	ER	
Start	dose=	100	m
g	
300	m
g	over	3-w
k	run-
in	follow
ed	by	
random
isation	to	
300	m
g	or	200	m
g	
vs.	
Placebo
RM
:	low
-dose	Aspirin	
or	Acetam
inophen	
(dosage	N/S)
N=	129	treated	w
ith	
20	M
M
E
N=	128	treated	w
ith	
30	M
M
E	
Total:	378/619	patients	(61%
)
Reasons	for	discontinuation	at	Titration	
and	Treatm
ent	(300	m
g	:	200	m
g	:	
Placebo):
Adverse	event	(128,	13:13:18)
Lack	of	efficacy	(41,	13:11:21)
Noncom
pliance	(21,	-:-:-)
Subject	choice	(20,	5:9:3)
Investigator	choice	(2,	-:-:-)
Other	(21,	11:9:19)
Total:	499	(80.6%
)	patients	
had	AEs	during	titration;	5%
	of	
the	AEs	w
as	considered	serious	
Sleep-related	AE/SAE:	
(300m
g	:	200m
g	:	Placebo:	Not	
random
ised)
during	titration
Som
nolence	(13	:	17	:	16	:	38)
Fatigue	(9	:	8	:	6	:	13)
Q
uality	of	Sleep	(0=very	poor,	100=excellent)	(self	report)
Both	tram
adol	groups	show
ed	im
proved	quality	of	sleep	
during	the	12-w
k	treatm
ent	phase,	com
pared	to	pre-
treatm
ent	.	Both	tram
adol	groups	show
ed	significantly	
greater	im
provem
ent	than	placebo	over	the	12-w
k	
treatm
ent	phase	(Tram
adol	300m
g	=	49.8±24.4,	Tram
adol	
200m
g	=	54.2±27,	Placebo	=	44.7±25.8).	No	difference	
betw
een	the	tram
adol	groups.
Pain	intensity	(0-100	VAS)	(self	report)
Both	tram
adol	groups	show
ed	significantly	greater	
im
provem
ent	than	placebo	over	the	12-w
k	treatm
ent	
phase	(Tram
adol	300m
g	=	30.5,	±23,	Tram
adol	200m
g	=	
34.1±27.1,	Placebo	=	40.3±25.2).	No	difference	betw
een	
tram
adol	groups.
Pain	disability	(Roland	Disability	Index)	(self	report)
Both	tram
adol	groups	show
ed	significantly	low
er	
disability	than	placebo	over	the	12-w
k	treatm
ent	phase	
(300m
g	=	8.2±5.5,	200m
g	=	8.5±5.9,	placebo	=	9.8±5.9).	
No	difference	betw
een	tram
adol	groups.
High
W
ebster	et	al.,	2015	
[37];	USA
Titration	phase:		
Hydrom
orphone,	IR	
(14	days	adjustm
ent;	
7	days	stabilisation)
2,	4	or	8	m
g	tablet	
every	4-6	hrs
Study	treatm
ent:		
Hydrom
orphone,	ER	
8,	12,	or	16m
g		
tablets,	1tablet	of	
m
edication	a	day	+	1	
tablet	of	placebo.
M
ean:	10	m
g/day.		
M
orning	dose	Q
AM
:	
08:00-10:00
vs.	
Evening	dose	Q
PM
:	
20:00-22:00
RM
:	Acetam
inophen	
(<1000	m
g/day)
Treatm
ent	m
ax	dose:	
N/R
M
ean	dose:	40	M
M
E
Total:	10/22	(45.5%
)
Reasons	for	discontinuation	at	Titration	
and	Treatm
ent:	
	Did	not	titrate	(4,-)
Severe	sleep	apnoea	(2,-)
Patient	decision	(1,-)	
Patient	non-com
pliance	(-,	1)
Non-com
pliance	(-,	1)
High	AHI	(-,	1)
Total:	51;	treatm
ent-em
ergent	
AEs	occurred	in	68%
,	29%
	and	
40%
	of	patients	w
ith	IR	
hydrom
orphone,	ER	
hydrom
orphone	Q
AM
	and	ER	
hydrom
orphone	Q
PM
	dosing.
Sleep-related	AE/SAE:	
Titration	
Fatigue	(5)
Som
nolence	(2)
Treatm
ent	(Q
AM
	:	Q
PM
)
Som
nolence	(0	:	1)
PSG	(objective)
Q
PM
	had	higher	no.	of	apneas,	AHI	and	CAI	vs.	no	
treatm
ent.	All	treatm
ent	groups	had	few
er	body	position	
changes,	less	leg	m
ovem
ents	and	shorter	w
ake	tim
e	after	
sleep	onset	vs.	no	treatm
ent.	Q
PM
	had	less	leg	
m
ovem
ent	than	Q
AM
	and	no	treatm
ent,	and	higher	sleep	
efficiency	(83.6±10)	vs.	no	treatm
ent	(76.4±12.5).	
M
odified	M
OS-Sleep	Scale	(self	report)
No	differences	in	M
OS	scores	betw
een	Q
AM
	and	Q
PM
	or	
betw
een	these	treatm
ents	w
ith	IR	hydrom
orphone.	Q
AM
	
had	im
proved	sleep	quality	vs.	no-treatm
ent	baseline.	All	
3	Rx	groups	show
ed	im
provem
ent	in	sleep	disturbance,	
snoring,	aw
akening	short	of	breath,	&
	sleep	problem
	
index	vs.	no	treatm
ent.	Sleep	problem
	index	w
as	32.8±15	
for	Q
PM
,	36.1±17.9	for	Q
AM
,	38±14.8	for	IR	
hydrom
orphone,	&
	51.2±20.6	for	no	treatm
ent.
Sleep	diary		(self	report)
No	effect	betw
een	Rx	for	all	daily	sleep	param
eters.	
Pain	VAS	(Short-form
	M
cGill	Pain	Q
uestionnaire)	(self	
report)
Scores	significantly	im
proved	in	all	Rx	groups	vs.	no	
treatm
ent	(55.5±23.1),	but	only	Q
PM
	(38.3±22.4)	
im
proved	vs.IR	Hydrom
orphone	(47.2±23.8).	No	
significant	difference	betw
een	Q
AM
	(46±26.2)and	Q
PM
	
Daily	pain	intensity	(Daily	diary	-	NRS)	(self	report)
Tim
e	of	dosing	had	no	statistically	significant	effect	on	
SELF-REPORTED		pain.	Q
PM
	group	had	low
er	average	pain	
and	w
orst	pain	over	last	24	hours	(3.9±2,	4.7±2.2)	vs.	
Q
AM
	(4.5±1.9,	5.4±2.0)	and	IR	Hydrom
orphone	(4.7±1.9,	
5.6±2.0)	
High
Notes.	Included	studies	are	presented	by	lead	author's	alphabetical	order.	
N/S	=	Not	specified.	N/R	=	Not	reported.	N/A	=	Not	applicable.	+	=	And.	Vs.	=	Versus.	Rx	=	Treatm
ent.	Yr	=	Year.	M
th	=	M
onth.	W
k	=	W
eek.	Hr	or	h	=	Hour.	M
in	=	M
inute.	x/day	=	tim
es	per	day.	No.	=	Num
ber.	Avg	=	Average.	M
ax	=	m
axim
um
.
¶	See	page	8	in	text	for	M
M
E	calculation	m
ethods.	AE	=	Adverse	event.	SAE	=	Serious	adverse	event.	*Additional	notes.	#	inform
ation	based	on	a	linked	study	by	Hale,	Tudor,	Khanna	et	al.	(2007)	Clin	Ther,	29(5):874-88.	è
titrated	to.	SD=	Standard	deviation,	presented	in	
bracket	or	im
m
ediately	after	±.		^	Sum
m
ary	assessm
ents	based	on	results	of	our	risk	of	bias	assessm
ent	and	according	to	the	Cochrane	definition	of	low
	(low
	risk	of	bias	for	all	key	dom
ains),	unclear	(unclear	risk	of	bias	for	one	or	m
ore	key	dom
ains)	and	high	(high	risk	of	bias	
for	one	or	m
ore	key	dom
ains)	risk	of	bias	w
ithin	a	study.
Opioids:	unless	specified	otherw
ise,	m
edications	are	oral,	CR	=	Controlled	release,	ER	=	Extended	release,	IR	=	Im
m
ediate	release,	SR	=	Slow
	release,	SuR	=	Sustained	release,	Q
AM
=	m
orning	dosing,	Q
PM
:	evening	dosing.	
AHI	=	Apnoea-hypopnoea	Index.	AUCM
Bavg	=	average	area	under	the	curve	m
inus	baseline	in	VAS	pain	scores.	BS-11	=	Box	Scale	11	or	Num
eric	11-point	Box.	BPI	=	Brief	Pain	Inventory.	CAI	=	Central	Apnoea	Index.	ESS	=	Epw
orth	Sleepiness	Scale.	EORTC	Q
LQ
-C30	=	European	
Organisation	for	Research	and	Treatm
ent	of	Cancer	(EORTC)	Q
LQ
-C30	questionnaire.	M
M
E=	M
orphine	M
illigram
	Equivalent.	M
OS	Sleep	Scale	=	M
edical	Outcom
es	Study	(M
OS)	Sleep	Scale.	M
PQ
	=	M
cGill	Pain	Q
uestionnaire.	NIDPOE	=	the	issue	of	Notice	of	Initiative	of	
Disqualification	Proceedings	and	Opportunity	to	Explain	by	the	Food	and	Drug	Agency's	Division	of	Scientific	Investigation.	NRS	=	Num
eric	Rating	Scale.	PSG	=	Polysom
nography	PSQ
I	=	Pittsburgh	Sleep	Q
uality	Index.	REM
	=	rapid	eye	m
ovem
ent.	RM
	=	Rescue	m
edication.	
SPAASM
S	=	SPAASM
S	score	card	of	pain,	physical	activity,	additional	rescue	m
edication,	additional	GP/em
ergency	departm
ent	visits,	sleep	quality,	m
ood,	and	side	effects	(self-rated	by	participants).	VAS	=	visual	analogue	scale.	VHS	=	Verran	and	Snyder-Halpern	Sleep	Scale.	
W
OM
AC	=	W
estern	Onatario	and	M
cM
aster	Universities	Osteoarthritis	Index
Supplementary Materials 1 – Search Terms 
 
((( opioid* OR opiate* ) AND (pain OR chronic pain OR nonmalignant pain OR non 
cancer pain OR intractable pain OR recurrent pain) AND ( sleep* OR insomnia* OR 
polysomnogr* OR PSG OR actigr* OR wake* OR (apnea OR apnoea) OR drows* 
OR respirat* OR breathing OR restless leg OR myoclonus OR somnolence OR sleep 
architecture OR sleep physiology OR (diary OR log) OR dyssomnia* OR sleep 
initiation OR sleep maintenance ))) NOT (infant OR child OR pediatric OR surgery 
OR palliative OR epidural OR cannabis OR marijuana).	
Supplementary Materials 2 – Risk of Bias Assessment Results 
 
3.3.1 Random sequence generation 
Eight studies describing robust methods of randomising participants were judged as 
low risk (34, 36-40, 43, 48). Five non-randomised, single-treatment studies were judged as 
high risk (45-47, 49, 50). Five studies mentioning randomisation without adequate detail 
were judged as unclear risk (33, 35, 41, 42, 44).  
 
3.3.2 Allocation concealment 
Six studies outlining procedures to conceal the allocation were judged as low risk (34, 
36, 37, 39, 40, 43). Seven studies either non-randomized or that lacked adequate 
concealment procedures were judged as high risk (33, 38, 45-47, 49, 50). Five studies gave 
insufficient detail of allocation concealment and were judged unclear (35, 41, 42, 44, 48).  
 
3.3.3 Blinding of participants and personnel 
Three studies that described robust procedures to maintain blinding of participants 
and personnel were judged as low risk (34, 36, 40). One study that was single blind (49), 
nine studies that were open-label designs (2, 33, 38, 39, 43, 46-48, 50), and two studies that had 
periods of open-label assessment (titration phase (44) and baseline assessment (37)) were 
judged as high risk. Three studies that gave insufficient detail of blinding procedures 
were judged as unclear risk (35, 41, 42). 
 
3.3.4 Blinding of outcome assessment  
Four studies that described blinding the outcome assessor of sleep-relevant measures 
were judged as low risk (34, 40, 48, 49). Three studies that involved no blinding of the 
outcome assessor were judged as high risk (39, 46, 47). Ten studies that gave insufficient 
detail of blinding the outcome assessor (33, 35-38, 41, 42, 44, 45, 50) and one study that did not 
clearly define the outcome assessor (43) were judged as unclear risk.  
 
3.3.5 Incomplete outcome data 
Four studies that had acceptable and well-documented attrition were judged as low 
risk (33, 35, 39, 45). Eight studies that had significant attrition (34, 40, 43, 47, 48), attrition due 
to outcome-relevant factors (37), and/or attrition with unclear handling of missing data 
(36, 44, 48) were judged as high risk. Six studies that provided insufficient detail of 
attrition (36, 38, 41, 42, 46, 49) or unclear handling missing data (50) were judged as unclear 
risk.  
 
3.3.6 Selective reporting 
One study stated that certain results would be the subject of a future paper (36); all 
other studies reported the outcomes outlined in their methods sections. All studies 
were judged as unclear risk because no protocols could be found to assure that all 
investigated outcomes had been reported.  
 
3.3.7 Other bias 
Eleven studies had potential conflicts of interest whereby their authors or funding 
were affiliated with a pharmaceutical manufacturer of the study drug (35-40, 43-46, 49, 50). 
 
	
